US Pat. No. 9,406,789

NANOSCALE VARIABLE RESISTOR/ELECTROMECHANICAL TRANSISTOR

NEW YORK UNIVERSITY, New...

1. A nanodevice for use in an electrical circuit, comprising:
a dielectric having a dielectric constant;
a metal conductor nanowire coupled to the dielectric, the nanowire having at least one constriction with a reduced diameter;
and

at least one gate disposed about at least a portion of the dielectric and coupled to the nanowire at the at least one constriction
for activating change of state for the nanowire.

US Pat. No. 9,368,208

NON-VOLATILE LATCH USING MAGNETO-ELECTRIC AND FERRO-ELECTRIC TUNNEL JUNCTIONS

Board of Regents, The Uni...

1. A non-volatile memory circuit comprising:
a first access transistor, a second access transistor, a first inverter having a first n-type transistor and a first p-type
transistor, a second inverter having a second n-type transistor and a second p-type transistor, at least one magnetic device,
and a programming logic,

wherein the first access transistor connects a bit line to a first output node of the first inverter under control of a word
line coupled to a gate of the first access transistor,

wherein the second access transistor connects a bit bar line to a second output node of the second inverter under control
of the word line coupled to a gate of the second access transistor,

wherein the first output node is coupled to a second input node of the second inverter and the second output node is coupled
to a first input node of the first inverter,

wherein the at least one magnetic device is coupled to the first n-type transistor and the second n-type transistor, and
wherein the programming logic is coupled to at least one of the first output node and the second output node to program the
at least one magnetic device,

wherein the at least one magnetic device comprises a first magneto-electric device and a second magneto-electric device, wherein
a first bottom electrode of the first magneto-electric device receives an output of the programming logic coupled to the first
output node, wherein a second bottom electrode of the second magneto-electric device receives an output of the programming
logic coupled to the second output node, wherein a first free ferromagnetic (FM) layer of the first magneto-electric device
and a second free FM layer of the second magneto-electric device are coupled to each other, wherein a first pinned FM layer
having a first polarity is coupled to the first n-type transistor, and wherein a second pinned FM layer having a second polarity
opposite the first polarity is coupled to the second n-type transistor.

US Pat. No. 9,096,653

MULTICOMPONENT VACCINE FOR MALARIA PROVIDING LONG-LASTING IMMUNE RESPONSES AGAINST PLASMODIA

The United States of Amer...

1. An immunogenic conjugate comprising:
a peptide comprising at least one repeat circumsporozoite protein selected from the group consisting of (NPNA)x, (PNAN)x,
and (ANPN)x, wherein x is four to six;

covalently linked to at least one other immunogenic protein selected from the group consisting of bovine serum albumin, ovalbumin,
tetanus toxoid, diphtheria toxoid, cholera toxin, Clostridium difficile toxin A, Clostridium difficile toxin B, and Pseudomonas aeruginosa recombinant exoprotein A, wherein the conjugate elicits an immune response to a Plasmodium falciparum circumsporozoite protein in a subject.

US Pat. No. 9,144,573

PROSTAGLANDIN TRANSPORTER INHIBITORS

Albert Einstein College o...

1. A compound having the structure:

wherein R1 is:

and wherein R2 is:

or a pharmaceutically acceptable salt, ester or tautomer thereof.

US Pat. No. 9,230,045

LAYER-BY-LAYER QUANTIFICATION OF THE REMODELING OF THE HUMAN FOVEA IN NEURODEGENERATIVE DISEASE

The Research Foundation f...

1. A system for layer-by-layer quantification of the remodeling of the human fovea comprises:
a display device;
a model having parameters; and
a CPU comprising hardware configured to implement a module operable to find a fixed reference point in an inner retina, measure
thickness of the inner retina at the fixed reference point, for a range of finely sampled distances starting from the fixed
reference point, measure thickness at each finely sampled distance, compare, at each finely sampled distance, the measured
thickness with a normative base and obtain a plurality of curves for signal/noise ratios, evaluate area for each curve and
obtain a set of areas defining a distance from the fixed reference having highest sensitivity with respect to the fixed reference
point compared to the normative base, determine a largest area from the set of areas, create and display, on the display device,
a three dimensional re-creation of foveal architecture-based color-coded picture in accordance with the measured thickness
at each finely sampled distance and the largest area, enter the measured thickness into the model, obtain numerical solutions
for each parameter for a patient and for a control of the model and define percent change of the parameters for the patient
versus the parameters for the control.

US Pat. No. 9,278,112

CITRATE CONTAINING BEVERAGE

New York University, New...

1. A beverage comprising sodium citrate, potassium citrate, citric acid, magnesium salt and pyridoxine, wherein the magnesium
salt is magnesium citrate or magnesium hydroxide.

US Pat. No. 9,364,472

AMINO, AMIDO AND HETEROCYCLIC COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF

New York University, New...

1. A method for preventing, treating or ameliorating in a mammal a disease or condition that is causally related to RAGE activity
in vivo, which comprises administering to the mammal an effective disease-treating or condition-treating amount of a compound
according to formula B-VI:

or a pharmaceutically acceptable salt, solvate or prodrug thereof or stereoisomers, isotopic variants and tautomers thereof.

US Pat. No. 9,179,858

COMPUTER-ACCESSIBLE MEDIUM, SYSTEM AND METHOD FOR ASSESSING EFFECT OF A STIMULUS USING INTERSUBJECT CORRELATION

New York University, New...

1. A non-transitory computer-accessible medium containing executable instructions thereon, wherein when a processing arrangement
executes the instructions, the processing arrangement is configured to perform procedures comprising:
receive first information associated with at least one particular version of a stimuli;
receive second information associated with least one further version of the stimuli;
determine an inter-subject correlation (ISC) for each of the first information and the second information;
select at least one of the at least one particular version or the at least one further version based on the determined ISC;
and

at least one of display or store identifiers of particular portions of the stimuli in a storage arrangement in at least one
of a user-accessible format or a user-readable format;

wherein the identifiers are configured to provide to at least one of a user or a computer system access to certain portions
of at least one of a film or a video, and wherein the processing arrangement is further configured to, using the access, at
least one of edit or alter the certain portions of the at least one of the film or the video based on the selected at least
one particular version or the at least one further version.

US Pat. No. 9,505,798

STEROID COMPOUNDS AS RORYT MODULATORS AND USES THEREOF

New York University, New...

1. A method for treating or ameliorating in a mammal a disease or condition that is causally related to ROR?t activity in
vivo, wherein the disease or condition is arthritis, diabetes, multiple sclerosis, uveitis, psoriasis, asthma, bronchitis,
allergic rhinitis, chronic obstructive pulmonary disease, atherosclerosis, H. pylori infections, ulcers, inflammatory bowel disease, Crohn's disease, ulcerative colitis, sprue, food allergies or, experimental
autoimmune encephalomyelitis (EAE), which comprises administering to the mammal an effective disease-treating or condition-treating
amount of a compound according to formula III:

wherein
Y is CO2R8, CH2OH,


* denotes the attachment point; the subscript w is 0, 1, or 2;
the subscript x is 1, 2, or 3;
each R5 and R7 is independently H, substituted or unsubstituted alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R8 is H or substituted or unsubstituted alkyl;

each R1a and R1b is independently OH, or O-acyl; or R1a and R1b together form


* denote the attachment points;
each R6a and R6b is independently H, substituted or unsubstituted alkyl, cycloalkyl, aryl or heteroaryl;

each subscript n is independently 0, 1, 2, 3, 4, or 5; and
each dotted bond is independently a single or a double bond;
or a pharmaceutically acceptable salt, solvate or prodrug thereof;
and stereoisomers, isotopic variants and tautomers thereof.

US Pat. No. 9,353,078

AMINO, AMIDO AND HETEROCYCLIC COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF

New York University, New...

1. A method for treating or ameliorating in a mammal a disease or condition that is causally related to RAGE activity in vivo,
which comprises administering to the mammal an effective disease-treating or condition-treating amount of a compound according
to formula B-I?:

wherein
each A1, A2, A3, and A4 is independently CR4 or N; provided that only 1 or 2 of A1, A2, A3, and A4 are N at any one time;

Z is substituted amino, substituted hydroxyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
X is CR5a or N;

R1 is hydroxy, substituted hydroxyl, amino, or substituted amino;

R2 is H, alkyl or aryl;

R3a is H, substituted or unsubstituted alkyl,substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, halo,
or cyano;

each R4 is independently selected from H, OH, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted
or unsubstituted acyl, substituted or unsubstituted acylamino, substituted or unsubstituted alkylamino, substituted or unsubstituted
alkythio, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkylarylamino, substituted or unsubstituted
amino, substituted or unsubstituted arylalkyl, sulfo, substituted sulfo, substituted sulfonyl, substituted sulfinyl, substituted
sulfanyl, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted
arylsulfonyl, azido, substituted or unsubstituted carbamoyl, carboxyl, cyano, substituted or unsubstituted aryl, substituted
or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted
or unsubstituted dialkylamino, halo, nitro, and thiol;

R5a is independently H, substituted or unsubstituted alkyl,substituted or unsubstituted cycloalkyl, substituted or unsubstituted
aryl, halo, or cyano; or R5a and R3a may join together to form a substituted or unsubstituted carbocyclic or heterocyclic ring;

and each of the subscript m and n is independently 1, 2, or 3;
or a pharmaceutically acceptable salt, solvate or prodrug thereof;
or stereoisomers, isotopic variants and tautomers thereof;
wherein the disease or condition is selected from diabetes and its complications, atherosclerosis, peripheral vascular disease
and associated complications, cardiovascular disease nephropathy,retinopathy, cardio- and cerebrovascular ischemia/reperfusion
injury, heart attack, myocardial infarction, ischemic cardiomyopathy, cancer, tumor invasion and metastases, acute and chronic
inflammation, arthritis,allergy asthma, obesity, pollution-associated tissue or organ damage, infection, sepsis, pneumonia,
liver injury/damage, amyloidoses, skin disorders, colitis, lupus, and impaired wound healing.

US Pat. No. 9,286,962

MAGNETIC MEMORY SYSTEM AND METHODS IN VARIOUS MODES OF OPERATION

Raytheon BBN Technologies...

1. A system comprising:
a superconductor circuit to generate a magnetic signal;
a magnetic memory element to store data;
a link disposed between the superconductor circuit and the magnetic memory element; and
the superconductor circuit operable to transmit the magnetic signal to the magnetic memory element over the link to access
the magnetic memory element.

US Pat. No. 9,255,086

CONTROL OF HYPOXIA-INDUCIBLE GENE EXPRESSION WITH OLIGOOXOPIPERAZINE NONPEPTIDIC HELIX MIMETICS

New York University, New...

1. A method of reducing transcription of a gene in a cell, wherein transcription of the gene is mediated by interaction of
Hypoxia-Inducible Factor 1? with CREB-binding protein and/or p300, said method comprising:
contacting the cell with an oligooxopiperazine under conditions effective to reduce transcription of the gene, wherein the
oligooxopiperazine is an oligooxopiperazine of Formula I:

wherein:
each of R1, R2, R3, and R4 is independently an amino acid side chain, H, N(R)2, OR, halogen, an alkyl, or an aryl; wherein each R is independently H, an alkyl, or an aryl;

each R6 is independently H, N(R)2, OR, halogen, an alkyl, or an aryl; wherein each R is independently H, an alkyl, or an aryl;

A is X1 or C, wherein:

X1 is H, COR?, CO2R?, CONHR?, an alkyl, an aryl, an arylalkyl, a cycloalkyl, a heteroaryl, a protecting group for protection of an amine, a
targeting moiety, or a tag; wherein R? is H, an alkyl, an aryl, an arylalkyl, a cycloalkyl, a heteroaryl, a targeting moiety,
or a tag; and

C is a moiety of the formula

wherein:
each X? is independently H, COR?, CO2R?, CONHR?, N(R?)2, an alkyl, an aryl, an arylalkyl, a cycloalkyl, a heteroaryl, a targeting moiety, or a tag; wherein:

R? is H, an alkyl, an aryl, an arylalkyl, a cycloalkyl, a heteroaryl, a targeting moiety, or a tag; and
each R? is independently H, an alkyl, an aryl, an arylalkyl, a cycloalkyl, a heteroaryl, a targeting moiety, or a tag;
R0 is an amino acid side chain, H, N(R)2, OR, halogen, an alkyl, or an aryl;

wherein each R is independently H, an alkyl, or an aryl; and
R6 is H, N(R)2, OR, halogen, an alkyl, or an aryl; wherein each R is independently H, an alkyl, or an aryl; and

B is OR?, COR?, N(R??)2, an alkyl, an aryl, an arylalkyl, a cycloalkyl, a heteroaryl, a protecting group for protection of a carboxylic acid, a targeting
moiety, or a tag; wherein:

R? is H, an alkyl, an aryl, an arylalkyl, a cycloalkyl, a heteroaryl, a targeting moiety, or a tag; and
each R?? is independently H, CO2R?, CONHR?, an alkyl, an aryl, an arylalkyl, a cycloalkyl, a heteroaryl, a targeting moiety, or a tag;

wherein R1 and R2 are hydrophobic and R4 is a hydrogen bond acceptor or hydrogen bond donor, or A is a moiety of formula


 R0 and R3 are hydrophobic, and R4 is a hydrogen bond acceptor or hydrogen bond donor; and

with the proviso that at least one of the following conditions is not met: R1 is a leucine side chain R2 is a leucine side chain, and R4 is a glutamine side chain.

US Pat. No. 9,244,074

BIOMARKER OF ASBESTOS EXPOSURE AND MESOTHELIOMA

University of Hawaii, Ho...

1. A method of diagnosing asbestos exposure in a human subject, the method comprising:
contacting a sample of the human subject with a high-affinity monoclonal antibody specific for HMGB1, wherein the human subject
is suspected of prior occupational or environmental asbestos exposure;

determining whether the amount of the sample bound by the antibody specific for HMGB1 is greater than a predetermined level
of at least 3 ng/ml; and

diagnosing the human subject as having been exposed to asbestos when the amount of the sample bound by the antibody is greater
than the predetermined level.

US Pat. No. 9,233,237

APPARATUS AND METHOD FOR PERIODIC FLUID-DELIVERY/FLUID-REMOVAL CYCLES IN THE CRANIAL SUBARACHNOID SPACE TO TREAT CEREBRAL CORTICAL DISORDERS

NEW YORK UNIVERSITY, New...

1. A method for treating a brain of a subject, comprising:
implanting a fluid exchange device in a subdural or subarachnoid space of the brain, the fluid exchange device comprising
a body portion sized and shaped for placement entirely within the subdural or subarachnoid space, an inlet opening extending
through the body portion to a first fluid exchange port, and an outlet opening extending through the body portion to the first
fluid exchange port;

implanting a fluid delivery/withdrawal device at a location in the subject's body remote from a first target area of the subdural
or subarachnoid space, the first fluid delivery/withdrawal device including a delivery lumen coupled to the inlet opening
and an outlet lumen coupled to the outlet opening, the fluid delivery/withdrawal device being coupled to a source of a first
fluid; and

operating a control unit to administer the first fluid to the first target area via the inlet opening and withdraw fluid from
the first target area at predetermined periodic intervals and volumes, wherein the intervals and volumes are selected by the
control unit to reduce accumulation of inflammatory host responses in the target area.

US Pat. No. 9,567,378

IN SITU ORIENTED IMMOBILIZATION OF PROTEINS ON A SUPPORT

New York University, New...

1. A method of directing in situ oriented immobilization of a protein on a support, said method comprising:
providing a support;
contacting the support with a solution comprising:
a protein comprising a coupling moiety, wherein the protein is a recombinant fusion protein and the coupling moiety comprises
glutathione-S-transferase (GST) and

a glutathione molecule comprising a first group reactive with the support and a second group reactive with the coupling moiety,
wherein the glutathione molecule binds (i) the support at the first group and (ii) the coupling moiety at the second group,
thereby immobilizing and orienting, in situ, the protein on the support.

US Pat. No. 9,480,726

LEUKOTOXIN E/D AS A NEW ANTI-INFLAMMATORY AGENT AND MICROBICIDE

New York University, New...

1. A method of reducing the viral load in a subject having Human Immunodeficiency Virus (HIV) infection comprising:
selecting subject infected with an HIV strain that infects CCR5-positive cells of the subject and administering a composition
comprising an isolated Leukocidin E (LukE) protein; and an isolated Leukocidin D (LukD) protein that selectively deplete CCR5-positive
cells in the selected subject wherein said composition is administered in an amount effective to reduce HIV viral load in
the selected subject.

US Pat. No. 9,265,774

METHODS, COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING ANXIETY AND MOOD DISORDERS

New York University, New...

1. A pharmaceutical composition to treat an anxiety disorder or a mood disorder comprising a cocktail of at least two inhibitors
of central stress nuclei, wherein at least one inhibitor of the central stress nuclei is a compound according to formula IIIa,
IIIb, or IIIc:

or a pharmaceutically acceptable salt, or solvate thereof; and stereoisomers, isotopic variants and tautomers thereof.

US Pat. No. 9,242,066

SYSTEM AND METHOD FOR CIRCUITS TO ALLOW CPAP TO PROVIDE ZERO PRESSURE

New York University, New...

1. A system, comprising:
a respiratory mask adapted to cover at least one respiratory orifice of a patient;
a respiratory device configured to deliver a positive pressure gas flow;
a first conduit extending from a first end connected to the respiratory device to a second end connected to the respiratory
mask, the first conduit including a valve movable between a first position and a second position, the first position being
configured to seal an opening in a wall of the first conduit, and the second position being configured to obstruct air flow
through the first conduit to the respiratory mask;

a second conduit positioned within the first conduit and extending from a third end to a fourth end connected to the respiratory
mask, the third end being separate from the first end;

a sensing element for detecting data corresponding to a breathing pattern of a patient; and
a controller for controlling the positive pressure gas flow based on the data detected by the sensing element and moving the
valve to the first position when the positive pressure gas flow is above a predetermined pressure and to the second position
when the positive pressure from the respiratory device is below the predetermined pressure.

US Pat. No. 9,241,920

INHIBITION OF C-MYC UBIQUITINATION TO PREVENT CANCER INITIATION AND PROGRESSION

NEW YORK UNIVERSITY, New...

1. A method of inhibiting proliferation of leukemia cells said method comprising:
administering to a population of leukemia cells a Fbw7 inhibitor, wherein the Fbw7 inhibitor is 1-(2-carboxynaphth-lyl)-2-naphthoic
acid (SCF-12), in an amount.

US Pat. No. 9,125,747

IMPLANTS FOR THE TREATMENT OF OSTEOARTHRITIS OF THE KNEE

NEW YORK UNIVERSITY, New...

1. A method of providing a femoral implant to a knee with osteoarthritis, comprising the steps of:
a. resecting a portion of a femur of a patient, the resected portion comprising an arthritic lesion on a distal medial femoral
condyle of the femur;

b. providing a femoral implant to the resected femur, the implant being at least 8 mm in thickness and having a bearing surface
that is convex,
the implant being set into the resected femoral condyle such that the implant is flush with the articular surface of the cartilage
located at anterior and posterior locations of the knee, the implant projecting above the articular surface of the cartilage
in the center of the implant, the projection tapering flush with the articular surface of the cartilage at the medial and
lateral edges of the implant.

US Pat. No. 9,206,241

MODIFIED PROKARYOTIC UBIQUITIN-LIKE PROTEIN AND METHODS OF USE THEREOF

New York University, New...

1. A purified synthetic prokaryotic ubiquitin-like protein (Pup) comprising the amino acid sequence spanning positions 1-63
of Pup as set forth in SEQ ID NO: 2, wherein the carboxylate of amino acid glycine at position 63 of SEQ ID NO: 2 is attached
via a covalent linkage to a modified glutamic acid (Glu), wherein the modified Glu is attached via the gamma-carboyxlate side
chain of Glu to a synthetic fluorogenic or luminescent reporter moiety.

US Pat. No. 9,411,457

SENSOR HAVING A SET OF PLATES, AND METHOD

New York University, New...

1. A sensor comprising:
a set of plates which form a plate matrix that are in contact from their bottom at the corners with a set of protrusions that
are in contact from above with a plurality of intersections, each having a sensing element, of a grid of wires disposed on
a base, and a top surface layer that is disposed atop the set of plates, so that force imparted from above onto the top surface
layer is transmitted to the plates and thence to the protrusions, and thence to the intersections of the grid of wires which
are thereby compressed between the base and protrusions; and that the protrusions above thereby focus the imparted force directly
onto the intersections, each plate made of a piece of plastic, metal, wood or glass; and

a computer in communication with the grid which causes prompting signals to be sent to the grid and reconstructs a continuous
position of force on the surface from interpolation based on data signals received from the grid and across and in between
the plates as the force moves from one plate to another plate.

US Pat. No. 9,101,600

COMPOUNDS AS ROR?T MODULATORS AND USES THEREOF

New York University, New...

1. A method for treating in a mammal an autoimmune or inflammatory disease or condition, which comprises administering to
the mammal an effective disease-treating or condition-treating amount of a compound according to formula I:

wherein
R1 is OH, or substituted or unsubstituted alkoxy;

R2 is H, or Me;

each R3 and R4 is independently selected from H, OH, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted
or unsubstituted acyl, substituted or unsubstituted acylamino, substituted or unsubstituted alkylamino, substituted or unsubstituted
alkylthio, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkylarylamino, substituted or unsubstituted
amino, substituted or unsubstituted arylalkyl, sulfo, substituted sulfo, substituted sulfonyl, substituted sulfinyl, substituted
sulfanyl, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted
arylsulfonyl, azido, substituted or unsubstituted carbamoyl, carboxyl, cyano, substituted or unsubstituted aryl, substituted
or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted
or unsubstituted dialkylamino, halo, nitro, and thiol; and

each n1 and n2 is independently 1, 2, 3, 4 or 5;
or a pharmaceutically acceptable salt or solvate thereof; and
stereoisomers, isotopic variants and tautomers thereof, wherein the autoimmune or inflammatory disease or condition is arthritis,
diabetes, multiple sclerosis, uveitis, psoriasis, asthma, bronchitis, allergic rhinitis, chronic obstructive pulmonary disease,
atherosclerosis, H. pylori infection, ulcers resulting from H. pylori infection, inflammatory bowel diseases, Crohn's disease, ulcerative colitis, sprue, food allergies, experimental autoimmune
encephalomyelitis (EAE).

US Pat. No. 9,155,789

USE OF ALLOGENIC OR SYNGENIC MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) MOLECULES AS UNIVERSAL ADJUVANTS FOR VACCINES AGAINST NEOPLASTIC DISEASE, INFECTION AND AUTOIMMUNE DISEASE

NEW YORK UNIVERSITY, New...

19. A method for augmenting an immune response to a sporozoite stage of malaria in a susceptible mammalian host comprising
conjointly administering to the host: (i) at least one malaria sporozoite-specific antigen in a first amount, and (ii) a vector
or a cell encoding an allogenic MHC molecule in a second amount; the first and second amounts being effective in combination
to augment the immune response mounted against the antigen by the host as compared to the immune response that the host could
have mounted upon the administration of the first amount of the antigen without the conjoint administration of the vector
or cell encoding the MHC molecule, wherein said MHC molecule induces an allo-reactive T cell response.
US Pat. No. 9,157,080

COMPOSITIONS AND METHODS FOR TREATMENT, DIAGNOSIS AND PROGNOSIS OF MESOTHELIOMA

New York University, New...

1. A method of treating malignant mesothelioma, inhibiting progression of malignant mesothelioma or decreasing malignant mesothelioma
growth and invasion comprising administering to a human subject in need thereof a composition comprising a human miR-31 nucleic
acid comprising SEQ ID NO: 1.
US Pat. No. 9,091,689

METHODS OF TREATING AND PREVENTING STAPHYLOCOCCUS AUREUS INFECTIONS AND ASSOCIATED CONDITIONS

New York University, New...

1. A composition comprising:
one or more Staphylococcus aureus-specific Leukocidin E (LukE) antibodies or fragments thereof, wherein said LukE antibody or fragment thereof binds an epitope
selected from the group consisting of amino acid residues 3-13 of SEQ ID NO:11, amino acid residues 32-47 of SEQ ID NO:11,
amino acid residues 57-75 of SEQ ID NO:11, amino acid residues 126-139 of SEQ ID NO: 11, amino acid residues 151-156 of SEQ
ID NO: 11, amino acid residues 162-198 of SEQ ID NO: 11, amino acid residues 230-273 of SEQ ID NO:11, and amino acid residues
272-283 of SEQ ID NO:11, and a pharmaceutically acceptable carrier.

US Pat. No. 9,464,296

METHODS OF AFFECTING NITROGEN ASSIMILATION IN PLANTS

New York University, New...

1. A transgenic plant that exhibits increased nitrogen-assimilation capacity as compared to a wild-type plant, the transgenic
plant having a first gene construct comprising a polynucleotide encoding Arabidopsis Basic Leucine Zipper 1 (bZIP1) operatively linked to a first promoter with activity in plants, and a second gene construct
comprising a polynucleotide encoding Arabidopsis Golden 2-like 1 (GLK1) operatively linked to a second promoter with activity in plants, wherein the first and second promoters
are optionally (a) a constitutive, tissue-specific, or inducible promoter or (b) associated with a constitutive or inducible
regulatory element, and wherein the first and second promoters can be the same or different.

US Pat. No. 9,389,842

CONFIGURATION-PRESERVING PREPROCESSOR

New York University, New...

1. A system comprising:
one or more processors; and
one or more computer storage media storing one or more modules of computer program instructions executed by the one or more
processors, the one or more modules of computer program instructions comprising:

a lexer module to:
generate a plurality of tokens from one or more source files, the one ormore source files including source code in a first programming language, the source code comprising a macro invocation containing
one or more static conditionals that include a conditional expression and branch code that is operative when the conditional
expression is true, and wherein various configurations are possible based upon the conditionals and the conditionals can alter
the macro invocation by changing a name or argument of the macro invocation; and
a configuration-preserving preprocessor module to:
determine that a first static conditional in the macro invocation includes one or more nested static conditionals within the
branch code associated with the first static conditional; and

hoist each of the one or more nested static conditionals around the macro invocation to a beginning of the branch code associated
with the first static conditional, wherein each innermost branch code does not contain a static conditional, and wherein each
possible configuration is preserved.

US Pat. No. 9,354,490

METHOD, COMPUTER-ACCESSIBLE, MEDIUM AND SYSTEMS FOR FACILITATING DARK FLASH PHOTOGRAPHY

New York University, New...

1. A process for dark flash photography, comprising:
(a) obtaining a first image of at least one of a scene or one or more subjects illuminated by light comprising ambient light;
(b) obtaining a second image of the at least one of the scene or one or more subjects illuminated with light comprising ultra-violet
light and infra-red light; and

(c) using a computer hardware arrangement, generating a third image based on the first image and the second image by selecting
less than all edges of the second image.

US Pat. No. 9,317,154

METHOD AND APPARATUS FOR SENSING UTILIZING TILES

New York University, New...

1. An apparatus for sensing comprising:
a computer and a plurality of individual sensing tiles in communication with the computer that form a sensor surface that
detects force applied to the surface and provides a signal corresponding to the force to the computer which produces from
the signal a time varying continuous image of force applied to the surface, where the surface is contiguous, and detected
force can be sensed in a manner that is geometrically continuous and seamless on a surface, each tile having protrusions;
and

bridging plates which span across pairs of the protrusions on different sensing tiles, the computer causes prompting signals
to be sent to the sensing tiles and reconstructs a continuous position of force on the surface from interpolation based on
data signals received from the sensing tiles, each sensing tile has a microcontroller that produces data packets that have
the sensing tile's identity from which the data packets are produced and which are sent over a common communication protocol
shared by the microcontroller of each sensing tile to the computer, a printed circuit board having the microcontroller and
a layer having an inner face below the protrusions with a cavity in which the printed circuit board is disposed.

US Pat. No. 9,168,344

SYSTEM AND METHOD FOR DIAGNOSIS AND TREATMENT OF A BREATHING PATTERN OF A PATIENT

New York University, New...

1. A system, comprising:
a flow sensor provided in an airflow path and measuring data corresponding to a patient's breathing patterns; and
a processing arrangement configured to analyze the breathing patterns to determine whether the breathing patterns are indicative
of a troubled wakefulness state; and

a generator configured to supply an airflow to an airway of the patient and to reduce a pressure of the airflow supplied to
an airway of the patient from a first pressure to a second pressure when the processing arrangement determines that the breathing
patterns are indicative of the troubled wakefulness state, the second pressure being lower than the first pressure.

US Pat. No. 9,364,449

PEPTOID AND SYNTHETIC OLIGOMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING SAME

New York University, New...

1. A synthetic oligomer
(i) wherein the synthetic oligomer is
X-Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-Ile-Ala-Y
(SEQ ID NO: 28);

or a salt thereof, and stereoisomers, isotopic variants and tautomers thereof;
and wherein at least one and up to 35 amino acid residues are replaced with monomers independently selected from Nap, Nab,
Nah, Ngb, Npm, Nnm, Ndp, Nip, Nib, Nmg, and Nchm;

or
(ii) wherein the synthetic oligomer is X-Gly-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Y (SEQ ID NO: 32); or a salt thereof,
and stereoisomers, isotopic variants and tautomers thereof; and wherein at least one and up to 5 amino acid residues are replaced
with monomers independently selected from Nap, Nab, Nah, Ngb, Npm, Nnm, Ndp, Nip, Nib, Nmg, and Nchm;

or
(iii) wherein the synthetic oligomer is X-Gly-Lys-Leu-Val-Phe-Phe-Ala-Glu-Y (SEQ ID NO: 33); or a salt thereof, and stereoisomers,
isotopic variants and tautomers thereof;

and wherein at least one and up to 4 amino acid residues are replaced with monomers independently selected from Nap, Nab,
Nah, Ngb, Npm, Nnm, Ndp, Nip, Nib, Nmg, and Nchm;

or
(iv) wherein the synthetic oligomer is X-Gly-Lys-Leu-Val-Phe-Phe-Y (SEQ ID NO: 34); or a salt thereof, and stereoisomers,
isotopic variants and tautomers thereof; and wherein at least one and up to 4 amino acid residues are replaced with monomers
independently selected from Nap, Nab, Nah, Ngb, Npm, Nnm, Ndp, Nip, Nib, Nmg, and Nchm;

and
wherein:
Phe is phenylalanine or cyclohexylalanine;

and
provided that a) the monomer or monomers adjacent to Nmg are other than Gly, Nmg, Ser, Ile, or Tyr; and b) none of -Gly-residues
is replaced with Nmg.

US Pat. No. 9,241,950

MIR-33 INHIBITORS AND USES THEREOF TO DECREASE INFLAMMATION

New York University, New...

1. A method for reducing inflammation comprising administering to a subject with an inflamed tissue comprising M1 macrophages,
an inhibitor that specifically targets miR-33 in an amount effective to reduce inflammation in the tissue of the subject.
US Pat. No. 9,409,146

METHOD FOR TREATING AMYLOID DISEASE

New York University, New...

1. A method of treating an amyloid disease in a patient in need of such treatment comprising filtering the blood of the patient
through a membrane, filter or column, thereby removing circulating amyloid-beta from the patient and reducing amyloid-beta
burden within the brain of the patient, wherein the membrane, filter or column comprises an antibody or antibody fragment
which is bound or conjugated to the membrane, filter, or column and which binds to amyloid-beta, and wherein the patient is
not exposed directly to said antibody or antibody fragment.

US Pat. No. 9,309,230

OLIGOOXOPIPERAZINES AND METHODS OF MAKING AND USING THEM

New York University, New...

14. A method of making an oligooxopiperazine of Formula IA:
wherein:
each of R1, R2, R3, R4, and R5 is independently an amino acid side chain, H, N(R)2, OR, halogen, an alkyl, or an aryl; wherein each R is independently H, an alkyl, or an aryl;

each R6 is independently H, N(R)2, OR, halogen, an alkyl, or an aryl; wherein each R is independently H, an alkyl, or an aryl;

X1 is H, COR?, CO2R?, CONHR?, an alkyl, an aryl, an arylalkyl, a cycloalkyl, a heteroaryl, a protecting group for protection of an amine, a
targeting moiety, or a tag; wherein R? is H, an alkyl, an aryl, an arylalkyl, a cycloalkyl, a heteroaryl, a targeting moiety,
or a tag; and

E is X2 or F, wherein:

X2 is H, COR?, CO2R?, CONHR?, an alkyl, an aryl, an arylalkyl, a cycloalkyl, a heteroaryl, a protecting group for protection of an amine, a
targeting moiety, or a tag; wherein R? is H, an alkyl, an aryl, an arylalkyl, a cycloalkyl, a heteroaryl, a targeting moiety,
or a tag; and

F is a moiety of the formula

 wherein:
R6 is H, N(R)2, OR, halogen, an alkyl, or an aryl; wherein each R is independently H, an alkyl, or an aryl;

R7 is an amino acid side chain; and

Y is OR?, COR?, N(R??)2, an alkyl, an aryl, an arylalkyl, a cycloalkyl, a heteroaryl, a protecting group for protection of a carboxylic acid, a targeting
moiety, or a tag; wherein:

R? is H, an alkyl, an aryl, an arylalkyl, a cycloalkyl, a heteroaryl, a targeting moiety, or a tag; and
each R?? is independently H, CO2R?, CONHR?, an alkyl, an aryl, an arylalkyl, a cycloalkyl, a heteroaryl, a targeting moiety, or a tag;
(i) wherein said method comprises:
providing a compound of Formula III:

 wherein:
PG is a protecting group for the protection of an amine;
R8 is an amino acid side chain, H, N(R)2, OR, halogen, an alkyl, or an aryl; wherein each R is independently H, an alkyl, or an aryl; and

R9 is —O-Res or —NH-Res, wherein Res is a solid phase peptide synthesis resin;

providing a compound of Formula IV1:


 wherein R10 is —OH or a halide; and

reacting the compound of Formula III with a first alkylating agent and the compound of Formula IV1 under conditions effective to produce a compound of Formula V:


wherein:
if E is not —CR6R7—CO—Y, where R7 is the same as R8 and Y is the same as R9, said method further comprises converting —CR6R8—CO—R9 in the compound of Formula V to E; and

if X1 is not hydrogen, said method further comprises converting the N-terminal hydrogen in the compound of Formula V to X1;
or (ii) wherein said method comprises:
providing a compound of Formula X:

 wherein:
PG1 is a protecting group for the protection of an amine, and

R10 is —OH or a halide;

providing a compound of Formula XI5/8:


 wherein:
PG2 is a protecting group for the protection of a carboxylic acid; and

R8 is an amino acid side chain, H, N(R)2, OR, halogen, an alkyl, or an aryl; wherein each R is independently H, an alkyl, or an aryl; and

reacting the compound of Formula X with the compound of Formula XI5/8 under conditions effective to produce a compound of Formula XII:


wherein:
if E is not —CR6R7—CO—Y, where R7 is the same as R8 and Y is the same as PG2, said method further comprises converting —CR6R8—CO—PG2 in the compound of Formula XII to E; and

wherein if X1 is not PG1, said method further comprises converting PG1 in the compound of Formula XII to X1.

US Pat. No. 9,295,431

CONSTRUCTING A 3-DIMENSIONAL IMAGE FROM A 2-DIMENSIONAL IMAGE AND COMPRESSING A 3-DIMENSIONAL IMAGE TO A 2-DIMENSIONAL IMAGE

New York University, New...

1. A method for generating a three-dimensional image of an object, comprising:
receiving a plurality of blurred two-dimensional images captured using an optic system;
computationally generating, by a processor, a plurality of simulated blurred images corresponding to one of the plurality
of blurred two-dimensional images, each of the plurality of simulated blurred images using a different standard deviation
of a blur function distribution on the one of the plurality of blurred two-dimensional images, each standard deviation corresponding
to a respective depth;

determining, by a processor, a z-axis registry of a point spread function for the optic system, the determining comprising:
using best fit parameters to minimize mean square error between the plurality of blurred two-dimensional images and the plurality
of simulated blurred images to provide a depth estimation for a given blur of each of the plurality of simulated blurred images;
and

correlating each of the depth estimations to a magnitude of blur of each of the plurality of simulated blurred images and
recording in the z-axis registry;

receiving a blurred two-dimensional object image;
deconvoluting, using a processor, the blurred two-dimensional object image using the point spread function for the optic system,
to generate a stack of non-blurred two-dimensional images, each non-blurred image having a corresponding z-axis registry depth
estimation; and

constructing a three-dimensional image from the stack of two-dimensional images using the corresponding z-axis registry depth
estimations.

US Pat. No. 9,498,495

METHODS FOR IN VITRO DIFFERENTIATION OF TH-17+ CELLS

New York University, New...

1. A purified, homogeneous population of antigen naive human Th-IL17+ cells, wherein the purified, homogeneous population
comprises about or at least 109 antigen naive human Th-IL17+ cells and the purified, homogeneous population of antigen naive human Th-IL17+ cells does not
include Th-IL17+ cells expressing cellular markers of Th1, Th2, or Treg cells.

US Pat. No. 9,443,141

METHOD, SYSTEM, AND COMPUTER-ACCESSIBLE MEDIUM FOR CLASSIFICATION OF AT LEAST ONE ICTAL STATE

New York University, New...

1. A method for classifying at least one state of a subject, comprising:
receiving physiological data for the subject, the physiological data including a plurality of features having at least a first
feature and a second feature that are based on a respective measure of a synchronization for at least one pair of channels,
wherein the synchronization associated with (i) the first feature is over a first time period; and (ii) the second feature
is over a second time period;

generating an array of the features having the first and second features as entries in the array;
generating a multilayer convolutional neural network, wherein a first layer and a second layer of the multilayer convolutional
neural network is based on a convolution across time, and a third layer of the multilayer convolutional neural network is
based on a convolution across time, space and frequency; and

using a computer hardware arrangement, classifying the at least one state based on information provided in the array using
the at least one multilayer convolutional neural network.

US Pat. No. 9,402,558

SYSTEM AND METHOD FOR PAIN DETECTION AND COMPUTATION OF A PAIN QUANTIFICATION INDEX

NEW YORK UNIVERSITY, New...

1. A method of detecting pain in a subject, comprising the steps of:
comparing, using a processor, brain wave data generated based on brain wave activity of the subject to at least one source
of reference data to generate comparison data, the reference data corresponding to at least one of (i) population normative
data indicative of brain wave activity of a first plurality of individuals in an absence of pain, (ii) population reference
data indicative of brain wave activity of a second plurality of individuals generated in response to pain events inflicted
on the second plurality of individuals, (iii) subjective population reference data indicative of brain wave activity of a
third plurality of individuals reporting a sensation of pain, and (iv) population of reference data indicative of brain wave
activity of a fourth population of individuals following an intervention which has changed a subjective report of pain;

inputting, using the processor, the comparison data into at least one of a first classifier function A indicating a probability
score that pain is being sensed and a second classifier function B indicating a probability score that pain is not being sensed;

determining, using the processor, a presence of pain experienced by the subject as a function of the at least one probability
score, wherein the pain is not elicited by a sensory stimulus, the determining step comprising comparing the probability score
reflecting the presence of pain to the probability score reflecting that pain is not being sensed to calibrate a pain quantification
index including values corresponding to one of a plurality of levels of pain and a plurality of types of pain, wherein the
pain is not elicited by a sensory stimulus, and the types of pain include chronic and acute;

quantifying, using the processor, a level of pain experienced by the subject as a function of the comparison data; and
regulating an amount of analgesic administered to the subject by a patient controlled anesthetic apparatus as a function of
the comparison data and the level of pain.

US Pat. No. 9,399,666

INHIBITING INTERACTION BETWEEN THE HIF-1ALPHA AND P300/CBP WITH HYDROGEN BOND SURROGATE-BASED HELICES

New York University, New...

1. A peptide of formula I:
wherein
is a single or double carbon-carbon bond, wherein the double carbon-carbon bond is cis or trans;
each n is independently 1 or 2;
m is zero or any positive integer;
R1 is an amino acid, a peptide, —OR4, —CH2NH2, an alkyl group, an aryl group, or hydrogen, wherein R4 is alkyl or aryl;

or R1 has the formula:


 wherein A5 is a peptide, an amino acid residue, an acyl group, or hydrogen; and each R5 is independently an amino acid side chain, hydrogen, an alkyl group, or an aryl group;

R2 is hydrogen, an amino acid side chain, an alkyl group, or an aryl group;

R3 is a peptide, —OR6, —N(R7)2, an alkyl group, an aryl group, or hydrogen, wherein R6 is an alkyl group or an aryl group and each R7 is independently an amino acid side chain, hydrogen, an alkyl group, or an aryl group; and:

(i) A1 is Thr; A2 is Ser or Ala; A3 is Tyr or Ala; and A4 comprises the formula X1X2X3X4X5X6X7, wherein X1 is Asp or Asn; X2 is Val, Cys, or Ala; X3 is Glu or Gln; X4 is Val or Tyr; X5 is Asn or Arg; X6 is Ala; and X7 is Arg or absent; or

(ii) A1 and A2 are independently Glu or Gln; A3 is Leu; and A4 comprises the formula LRX8LX9, where L is Leu, R is Arg, X8 is Ala or Tyr, and X9 is Asp or Asn; and
wherein the peptide modulates the interaction between HIF-1? C-TAD and the p300/CBP CH1 domain,with the proviso that the peptide sequence does not consist of the sequence Thr-Ala-Ala-Asp-Cys-Glu-Tyr-Asn-Ala-Arg-NH2 (SEQ ID NO: 123).
US Pat. No. 9,315,549

TREATMENT METHODS USING ATOXIC NEUROTOXIN DERIVATIVES

New York University, New...

1. A treatment method comprising:
selecting a subject in need of therapeutic treatment involving induction of muscle paralysis and
contacting the subject with an isolated, physiologically active derivative of a wild type Clostridium botulinum neurotoxin, wherein the derivative of a Clostridium botulinum neurotoxin comprises one or more amino acid substitutions relative to the wild type Clostridium botulinum neurotoxin that reduces the metalloprotease activity responsible for the toxicity of wild type Clostridium botulinum neurotoxin and wherein the neurotoxin derivative comprises:

a light chain region and
a heavy chain region, wherein the light and heavy chain regions are linked by a disulfide bond, and wherein the light and
heavy chain regions are not truncated,

said contacting being carried out to induce muscle paralysis in the subject to treat the subject, with the proviso that the
neurotoxin derivative does not possess a cargo attachment peptide sequence at its N-terminus.

US Pat. No. 9,206,471

SELF-REPLICATING MATERIALS

NEW YORK UNIVERSITY, New...

1. A replicable artificial composition comprising,
at least two particles, A? and B?, having an A?-B? bond therebetween comprising a double-stranded DNA having an adenine-thymine/thymine-adenine
pairing, further comprising a surface-exposed first single-stranded nucleic acid on particle A? and a surface-exposed second
single-stranded nucleic acid on particle B?; and

at least two particles, A and B, having an A-B bond therebetween comprising a double-stranded DNA having an adenine-thymine/thymine-adenine
pairing, further comprising a surface-exposed third single-stranded nucleic acid on particle A and a surface-exposed fourth
single-stranded nucleic acid on particle B,

the first single-stranded nucleic acid on particle A? specifically and reversibly interacting with the surface-exposed third
single-stranded nucleic acid on particle A and the second single-stranded nucleic acid on particle B? specifically and reversibly
interacting with the surface-exposed fourth single-stranded nucleic acid on particle B;

wherein the A?-B? bond and the A-B bond are irreversible under conditions in which interactions of the third single-stranded
nucleic acid of particle A and the first single-stranded nucleic acid of particle A? and interactions of the fourth single-stranded
nucleic acid of particle B and the second single-stranded nucleic acid of particle B? are reversible;

further wherein the first single-stranded nucleic acid and the third single stranded nucleic acid do not hybridize through
adenine-thymine/thymine-adenine pairings and the second single-stranded nucleic acid and the fourth single-stranded nucleic
acid do not hybridize through adenine-thymine/thymine-adenine pairing and the irreversible conditions comprise psoralen mediated
cross-linking.

US Pat. No. 9,480,464

TISSUE COLLECTION SYSTEM

New York University, New...

1. A tissue collection system comprising:
an outer housing having opposed distal and proximal ends, wherein said distal end is provided with an inlet passage;
a first cylindrical fenestrated member within and immovable relative to said outer housing, wherein an outer tissue collection
chamber is defined between said outer housing and said first cylindrical fenestrated member;

a second cylindrical fenestrated member defining an inner tissue collection chamber and being positioned within and rotatable
relative to said first cylindrical fenestrated member between an open position in which the fenestrations of said first cylindrical
fenestrated member and the fenestrations of said second cylindrical fenestrated member are in registration with one another,
thereby permitting fluid communication between the inner tissue collection chamber and the outer tissue collection chamber,
and a closed position in which the fenestrations of said first cylindrical fenestrated member and the fenestrations of said
second cylindrical fenestrated member are not in registration with one another, thereby preventing fluid communication between
the inner tissue collection chamber and the outer tissue collection chamber;

a plunger axially movable within said second cylindrical fenestrated member between an advanced position near the distal end
of said outer housing and a retracted position near the proximal end of said outer housing, said plunger being rotatable to
move said second cylindrical fenestrated member between the open and closed positions;

an elongate rod being connected to said plunger to move said plunger axially between the advanced and retracted positions,
and extending through the proximal end of said outer housing, wherein said elongate rod comprises a plurality of longitudinally-extending
ribs;

and one or more stop units attached to the interior surface of said outer housing, extending into the outer tissue collection
chamber, and wherein at least one of said one or more stop units is positioned to engage said ribs,

wherein at least a portion of at least one of said one or more stop units is positioned proximal to said first and second
cylindrical fenestrated members to limit axial movement of said first and second cylindrical fenestrated members to positions
proximal of the at least one of said one or more stop units, and wherein rotation of said rod and said plunger rotates said
second cylindrical fenestrated member between the open and closed positions, and wherein at least one of said one or more
stop units engage at least one of said ribs at the open position and at the closed position.

US Pat. No. 9,354,725

TRACKING MOVEMENT OF A WRITING INSTRUMENT ON A GENERAL SURFACE

New York University, New...

1. A system comprising:
a document data store configured to store an image comprising first two or more handwritten words captured in the image;
a writing instrument comprising:
an optical tracking system configured to detect movement and record movement data of the writing instrument;
a camera configured to capture an image of an entirety of a general surface, wherein the general surface has second two or
more handwritten words written on the general surface and captured in the image of the general surface, wherein a boundary
of the entirety of the general surface is established by two or more reference points;

a digital signal processing (DSP) module configured to compare the captured image to the image to determine if it is a related
image, wherein the determination is based upon syntax of the first two or more handwritten words recognized in the captured
image and the second two or more handwritten words; and

a processor configured to:
determine a digital text document associated with the related image, wherein the digital text document comprises the text
equivalent of the second two or more handwritten words;

map a position of the writing instrument to a position within the digital text document;
convert the movement data into text; and
append the text to the digital text document based upon the mapped position within the digital text document.

US Pat. No. 9,236,103

BIPOLAR SPIN-TRANSFER SWITCHING

New York University, New...

1. A magnetic device comprising:
a magnetized polarizing layer;
a free magnetic layer, the free magnetic layer forming a first electrode and separated from the magnetized polarizing layer
by a first non-magnetic metal layer, the free magnetic layer having a magnetization vector having a first stable state and
a second stable state;

a reference layer forming a second electrode and separated from the free-magnetic layer by a second non-magnetic layer, the
reference layer having a fixed magnetization vector;

a current source that sources unipolar current through the magnetized polarizing layer, the free magnetic layer and the reference
layer, the current source is capable of outputting a first unipolar current pulse of a first duration and having a selected
amplitude, the first unipolar current pulse flowing orthogonally through the polarizing layer and having a positive polarity,
the current source also capable of outputting a second unipolar current pulse of a second duration and having a selected amplitude,
the second unipolar current pulse flowing orthogonally through the polarizing layer and having a negative polarity, and

wherein switching of the magnetization vector of the free magnetic layer from the first stable state to the second state is
initiated by application of the first unipolar current pulse, and wherein switching of the magnetization vector of the free
magnetic layer from the second stable state to the first stable state is initiated by application of the second unipolar current
pulse, wherein switching to the second stable state is independent of the first duration of the first unipolar current pulse,
and wherein switching to the first stable state is independent of the second duration of the second unipolar current pulse.

US Pat. No. 9,221,744

ASYMMETRIC CATALYSTS

New York University, New...

1. A catalyst of Formula I:
wherein:
each R1 is independently H; a lower alkyl; an aminyl; —OR6 wherein R6 is hydrogen or a lower alkyl; or the attachment point for A;

each R2 is independently H; a lower alkyl; an aminyl; or —OR6 wherein R6 is hydrogen or a lower alkyl;

each R3 and R4 is independently hydrogen; an alkyl; an alkenyl; an alkynyl; an aminyl; a carbonyl; a cycloalkyl; a heterocyclyl; an aryl;
a heteroaryl; an arylalkyl; an acyl; —OR5 wherein R5 is hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a heterocyclyl, an aryl, a heteroaryl, an arylalkyl, or an acyl;
or —(CH2)0-1N(R5)2 wherein each R5 is independently hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a heterocyclyl, an aryl, a heteroaryl, an arylalkyl,
or an acyl;

each A is a catalytic moiety;
B and D are atoms having different ionization potentials;
M is a metal;
X is absent, a solvent, or a counterion;
each is a bond of undefined stereochemistry; and
each - - - - is an optional bond with the proviso that:
(i) the bond between M and B is present and the bond between M and D is absent; or
(ii) the bond between M and B is absent and the bond between M and D is present.
US Pat. No. 9,370,491

POLYMER CARRIER

New York University, New...

1. A method for encapsulating a hydrophobic small molecule comprising:
combining a carrier polymer, wherein the carrier polymer comprises an amino acid sequence selected from the group consisting
of SEQ ID NOS: 3-17 and forms a hydrophobic pore with a threshold radius of 73 Å and a diameter that is 2-6 nm, and a hydrophobic
small molecule, wherein the hydrophobic small molecule binds to and is encapsulated by the hydrophobic pore of the carrier
polymer so as to form an encapsulated hydrophobic small molecule.

US Pat. No. 9,360,959

FUSING DEPTH AND PRESSURE IMAGING TO PROVIDE OBJECT IDENTIFICATION FOR MULTI-TOUCH SURFACES

Tactonic Technologies, LL...

1. An apparatus for inputting information into a computer about an object comprising:
a 3D sensor that senses 3D information including geometric information about the object's shape and position information and
produces a 3D output;

a 2D sensor that senses 2D information including position information about the object and produces a 2D output; and
a processing unit which receives the 2D and 3D output and produces a combined output that is a function of the 2D and 3D output,
including combining the 2D position information and the 3D position information to maintain tracking of the object, the 2D
sensor has two or more individual sensing tiles in communication with the processing unit that form a sensor surface that
detects force applied to the surface and provides a signal corresponding to the force to the processing unit which produces
from the signal a time varying continuous image of force applied to the surface, where the surface is contiguous, detected
force is sensed in a manner that is geometrically continuous and seamless on the surface, each tile comprises a grid of wires
that define intersections and areas of space between the wires, a set of protrusions that are in contact with a plurality
of intersections of the grid of wires, and a mechanical layer that is disposed atop the set of protrusions, so that force
imparted to the top of that mechanical layer is transmitted through the protrusions, and thence to the intersections, and
a force resistive material in proximity to a plurality of the intersections of the grid of wires in which is disposed only
in proximity to a plurality of the intersections of the grid of wires and in spaced relationship, the processing unit in communication
with the grid which causes prompting signals to be sent to the grid and reconstructs a continuous position of force on the
surface from interpolation based on data signals received from the grid wherein a protrusion is a rigid bump of plastic, metal,
wood or glass, having a curve at the protrusion's top, which focuses force onto an active area of a sensing element, and where
the force resistive material and an intersection of the plurality of the intersection of the grid of wires define the active
area of the sensing element where force from a protrusion on the sensing element is electrically measured with the prompting
signals in communication with the sensing element.

US Pat. No. 9,172,737

STREAMLOADING CONTENT, SUCH AS VIDEO CONTENT FOR EXAMPLE, BY BOTH DOWNLOADING ENHANCEMENT LAYERS OF THE CONTENT AND STREAMING A BASE LAYER OF THE CONTENT

New York University, New...

1. A computer-implemented method for playing media content, the computer-implemented method comprising:
a) requesting, by a client device, a content download service to serve one or more enhancement layers of the media content
for download by the client device;

b) receiving, by the client device, at least one of the requested one or more enhancement layers of the media content;
c) storing, by the client device, the received at least one of the requested one or more enhancement layers of the media content
for future use;

d) requesting, by the client device, a content streaming service to stream a base layer of the media content;
e) receiving, by the client device and after receipt of the at least one of the requested one or more enhancement layers of
the media content, a stream of the base layer of the media content;

f) decoding, by the client device, the media content using both (1) the stored at least one of one or more enhancement layers
of the media content and (2) the received stream of the base layer of the media content; and

g) playing, by the client device, the decoded media content,
wherein the downloaded enhancement layers of the media content are not subject to a contractual or legal restriction on buffer
size, but the streamed base layer of media content is subject to a contractual or legal restriction.

US Pat. No. 10,011,883

CAUSATIVE AGENTS AND DIAGNOSTIC METHODS RELATING TO RHEUMATOID ARTHRITIS

NEW YORK UNIVERSITY, New...

1. A method for diagnosing and treating new onset rheumatoid arthritis (NORA) in a subject, the method comprising:a) obtaining a biological sample from the subject;
b) detecting in the biological sample an increased amount of a Prevotella-related species of bacteria relative to that of a biological sample obtained from a control subject, wherein the Prevotella-related species of bacteria comprises SEQ ID NO: 1 or a variant thereof SEQ ID NO: 2 or SEQ ID NO: 3, thereby diagnosing NORA in the subject; and
c) administering a nonsteroidal anti-inflammatory drug (NSAID), a disease-modifying anti-rheumatic drug (DMARD), a steroid, an antibiotic, or an analgesic to the subject diagnosed with NORA.

US Pat. No. 9,216,180

PHARMACEUTICAL COMPOSITIONS AND TREATMENT OF GENETIC DISEASES ASSOCIATED WITH NONSENSE MEDIATED RNA DECAY

New York University, New...

1. A pharmaceutical composition comprising:
a compound of the formula (I):

a stereoisomer, pharmaceutically acceptable salt, oxide, solvate, or ester thereof, whereinA is selected from the group consisting of:
(1) absent;
(2) —O—;
(3) —CR11?CH—;

(4) —S—;
(5) —CHR12NH—;

(6) —NR13—;

(7) substituted or unsubstituted C3-8 cycloalkylene;

(8) substituted or unsubstituted arylene;
(9) substituted or unsubstituted heterocyclylene; and
(10) substituted or unsubstituted heteroarylenewherein the substituents of A are selected from the group consisting of halogen, OH, CN, NO2, C(O), NH2, H, C1-6 alkyl, C1-6 alkyl substituted with a —COOH, C2-6 alkenyl, C2-6 alkynyl, C4-7 cycloalkylalkyl, and monocyclic aryl;B is selected from the group consisting of:
(1) absent;
(2) —O—;
(3) —CR14?CH—;

(4) —NH—C(O)—;
(5) —C(S)—NH—;
(6) —N?CH—;
(7) substituted or unsubstituted C3-8 cycloalkylene;

(8) substituted or unsubstituted arylene;
(9) substituted or unsubstituted heterocyclylene; and
(10) substituted or unsubstituted heteroarylenewherein the substituents of B are selected from the group consisting of halogen, OH, CN, NO2, C(O), NH2, H, C1-6 alkyl, C1-6 alkyl substituted with a —COOH, C2-6 alkenyl, C2-6 alkynyl, C4-7 cycloalkylalkyl, and monocyclic aryl;L1 to L4 are independently selected from the group consisting of:
(1) absent;
(2) —S0-1—C1-6 alkylene —S0-1—;

(3) —S0-1—C2-4 alkenylene —S0-1—;

(4) —S0-1—C2-4 alkynylene —S0-1—; and

(5) —C(S)—NH—; and
(6) —NH—;X is C or N;Z is C, O, or S;Y is C or absent;R1 is absent or, if present, is H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, OR16, C(O)NR17R18, NR19C(O)R20;R2 is H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, OR16, NO2, C(O)N17R18, NR19C(O)R20, heterocyclyl or heteroaryl containing 1-5 heteroatoms selected from the group consisting of nitrogen, sulfur, and oxygen;R3 is H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, OR16, C(O)NR17R18, C(O)OR16, NR19C(O)R20;R4 is H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, OR16, C(O)OR16, C(O)NR17R18, NR19C(O)R16, heteroaryl containing 1-5 heteroatoms selected from the group consisting of nitrogen, sulfur, and oxygen;R5 is H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, OR16, C(O)OR16;R6 is H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, OR16, NR17R18, heteroaryl or heterocyclyl containing 1-5 heteroatoms selected from the group consisting of nitrogen, sulfur, and oxygen,
N?NR15;R7 is H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, OR16, NO2, NR19C(O)R20, S(O)2NR17R18;R8 is H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, OR16, NR19C(O)R20;R9 is H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, NO2, OR16, S(O)2NR21R22;R10 is H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, NR17R18, OR16;R1 to R10 are each optionally substituted 1 to 3 times with substituents selected from the group consisting of halogen, —OH, —OR21, —C(O)R21, —C(O)OR21, C(O)NR21R22, —NHR21, —NR21R22, —SR21, —S(O)R21, —S(O)2R21, NH2, CN, NO2, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, C4-7 cycloalkylalkyl, mono- or polycyclic aryl, and mono- or polycyclic heteroaryl containing 1 to 5 heteroatoms selected from
the group consisting of nitrogen, sulfur, and oxygen and, optionally, oxy substituted;R11 is H, C1-6 alkyl, C2-6 alkenyl, C3-6 alkynyl, NR19C(O)R20;R12 is H, C1-6 alkyl, C2-6 alkenyl, C3-6 alkynyl, C(O)OR16;R13 is NHNH;R14 is C(O)OR21;R10 and R12 can combine to form a —NH—C(O)— group;R13 and R15 can combine to form a —N—N?N— group;R15 to R22 are independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, C4-7 cycloalkylalky, C1-6 alkoxy, carboxy, a monocyclic or polycyclic aryl, or a monocyclic or polycyclic heterocyclyl or heteroaryl containing 1-5
heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, each R15 to R22 optionally substituted from 1-3 times with substituents selected from the group consisting of halogen, oxy, OH, CN, NO2, —C(O), NH2, H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, C4-7 cycloalkylalkyl, O-aryl substituted with C1-6 alkyl, C(O)NHCH2-heterocyclyl with 1-5 oxygen, sulfur, or nitrogen heteroatoms, heteroaryl with 1-5 heteroatoms selected from the group consisting
of oxygen, sulfur, or nitrogen heteroatoms, —S—C1-6 alkyl, and a monocyclic aryl;R21 and R22 can combine to form a 3-7-membered mono- or polycyclic heterocycle or mono- or polycyclic heteroaryl each containing 1-5 heteroatoms
selected from the group consisting of nitrogen, sulfur, and oxygen, where the heterocycle or heteroaryl are optionally substituted
from 1 to 3 times with substituents selected from the group consisting of halogen, OH, CN, NO2, NH2, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, C4-7 cycloalkylalkyl, a monocyclic aryl, and monocyclic heteroaryl; anda pharmaceutically acceptable carrier.
US Pat. No. 9,200,328

METHODS AND KITS FOR DIAGNOSING THE PROGNOSIS OF CANCER PATIENTS

NEW YORK UNIVERSITY, New...

1. A kit for determining expression of at least seven genes selected from the group consisting of JUNB, KLF4, FOXH1, FOS,
CLDN4, PADI4, B3GNT5, CDC7, PANK1, UNG, CBR3, and ATF3, comprising:
a set of affinity reagents to specifically detect expression of said at least seven genes, wherein said set of affinity reagents
contains fewer than 2,501 affinity reagents; and

a substrate on which each of said affinity reagents are physically immobilized at a particular predefined position.
US Pat. No. 9,149,519

CHIMERIC HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) WITH ENHANCED DENDRITIC CELL AND MACROPHAGE TROPISM COMPRISING THE SIMIAN IMMUNODEFICIENCY VIRUS (SIV) MINIMAL VPX PACKAGING DOMAIN

New York University, New...

1. A chimeric vector comprising HIV-1 nucleic acid sequences and SIVmac239 nucleic acid sequences, wherein the SIVmac239 nucleic acid sequences encode an SIVmac239 amino acid sequence consisting of a minimal Vpx packaging motif that confers Vpx packaging activity to the chimeric vector
and the nucleic acid sequences encoding the Vpx packaging motif are inserted after the nucleic acid codon that encodes amino
acid 14 of the p6 protein of the chimeric vector and the chimeric vector does not comprise any SIVmac nucleic acid sequences
except for the minimal Vpx packaging motif.
US Pat. No. 9,550,820

CHIMERIC FIBROBLAST GROWTH FACTOR 23/FIBROBLAST GROWTH FACTOR 19 PROTEINS AND METHODS OF USE

New York University, New...

1. An isolated chimeric protein comprising:
an N-terminus coupled to a C-terminus, wherein the N-terminus comprises an N-terminal portion from an FGF23 molecule and the
C-terminus comprises a C-terminal portion from an FGF19 molecule, wherein the isolated chimeric protein has the amino acid
sequence of SEQ ID NO: 254.

US Pat. No. 9,198,891

METHOD OF TREATING CANCER BY INHIBITION OF PROTEIN KINASE-LIKE ENDOPLASMIC RETICULUM PROTEIN KINASE

New York University, New...

1. A method of identifying compounds useful in decreasing protein kinase-like endoplasmic reticulum protein kinase (PERK),
said method comprising:
providing a first model consisting of a contiguous amino acid sequence fragment of SEQ ID NO: 1, wherein said contiguous amino
acid sequence fragment either (i) begins at amino acid residue Asp144 of SEQ ID NO: 1; (ii) ends at amino acid residue Ser191
of SEQ ID NO: 1; or (iii) begins at amino acid residue Asp144 and ends at amino acid residue Ser191 of SEQ ID NO:1;

providing one or more candidate compounds;
evaluating contact between the candidate compounds and the first model consisting of a contiguous amino acid sequence fragment
of SEQ ID NO: 1, wherein said contiguous amino acid sequence fragment either (i) begins at amino acid residue Asp144 of SEQ
ID NO: 1; (ii) ends at amino acid residue Ser191 of SEQ ID NO: 1; or (iii) begins at amino acid residue Asp144 and ends at
amino acid residue Ser191 of SEQ ID NO:1; and

identifying the compounds which, based on said evaluating, have the ability to bind to a contiguous amino acid sequence fragment
of SEQ ID NO: 1, wherein said contiguous amino acid sequence fragment either (i) begins at amino acid residue Asp144 of SEQ
ID NO: 1; (ii) ends at amino acid residue Ser191 of SEQ ID NO: 1; or (iii) begins at amino acid residue Asp144 and ends at
amino acid residue Ser191 of SEQ ID NO:1, as compounds potentially useful for decreasing PERK.

US Pat. No. 9,107,959

METHOD FOR SITE-SPECIFIC POLYVALENT DISPLAY ON POLYMERS

New York University, New...

1. A polyvalent linear peptoid comprising a plurality of heterogeneous backbone-attached pendant groups, wherein each of the
heterogeneous backbone-attached pendant groups is attached to the backbone of the linear peptoid via a triazole linkage group.
US Pat. No. 9,534,020

IMMUNOGENIC POLYPEPTIDES COMPRISING A MODIFIED LOOP PEPTIDE PRESENTING THE HIV-1 GP120 3074 MAB EPITOPE AND SCAFFOLD PROTEINS CONTAINING SAID PEPTIDE

New York University, New...

1. A recombinant immunogenic polypeptide comprising the amino acid sequence TESINIGPGQTFYA (SEQ ID NO:1).

US Pat. No. 9,492,439

AMIDO COMPOUNDS AS ROR?T MODULATORS AND USES THEREOF

New York University, New...

1. A compound according to formula III:

wherein
A is C, N, O, or S; m is 0 or 1;
n1 is 1, 2, 3, 4 or 5; n2 is 1, 2, or 3;
each R1a and R1b is independently H, or substituted or unsubstituted C1-C6 alkyl; or R1a and R1b joined together to form cycloalkyl ring;

R2 is H, substituted or unsubstituted C1-C6 alkyl, or aryl;

or one of R1a and R1b is joined to the C of CR2 to form a cyclopropyl ring; or R2 is joined to the C of CR1aR1b to form a cyclopropyl ring;

each R3 and R4 is independently selected from H, OH, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted
or unsubstituted acyl, substituted or unsubstituted acylamino, substituted or unsubstituted alkylamino, substituted or unsubstituted
alkylthio, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkylarylamino, substituted or unsubstituted
amino, substituted or unsubstituted arylalkyl, sulfo, substituted sulfo, substituted sulfonyl, substituted sulfinyl, substituted
sulfanyl, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted
arylsulfonyl, azido, substituted or unsubstituted carbamoyl, carboxyl, cyano, substituted or unsubstituted aryl, substituted
or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted
or unsubstituted dialkylamino, halo, nitro, and thiol; or any two adjacent R3 groups, any two adjacent R4 groups, or any two adjacent R4 and R7b groups, may joined together to form a substituted or unsubstituted carbocyclic or heterocyclic ring;

each R5a is alkyl, substituted alkyl, halo, haloalkyl, hydroxyalkyl, heteroaryl, CN, alkoxyalkyl, amido, hydroxyl, alkoxy or substituted
alkoxy; and t is 2 or 3;

each of R7a and R7b is independently OH, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, CN, halo, amido, or haloalkyl;

or a pharmaceutically acceptable salt, solvate or prodrug thereof;
and stereoisomers, isotopic variants and tautomers thereof;
provided that (R3)n1-Ph- group is other than substituted or unsubstituted benzopyranyl.

US Pat. No. 9,311,599

METHODS, SYSTEMS, AND MEDIA FOR IDENTIFYING ERRORS IN PREDICTIVE MODELS USING ANNOTATORS

Integral Ad Science, Inc....

1. A method for evaluating predictive models in classification systems, the method comprising:
causing, using a hardware processor, an input region to be presented to a user, wherein the input region receives an instance
from the user;

in response to receiving the instance from the user, retrieving, using the hardware processor, a classification assigned by
a predictive model for the received instance and a confidence value associated with the classification, wherein the classification
has been stored in association with the instance from the user in response to determining that the classification exceeds
a threshold value, and wherein the threshold value is set based at least in part on a penalty associated with misclassification
of the instance;

determining, using the hardware processor, whether the received instance has been incorrectly classified by the predictive
model;

in response to determining that the received instance has been incorrectly classified by the predictive model, (i) causing,
using the hardware processor, the received instance and a corrected classification provided by the user to be used as training
data to update the predictive model, and (ii) determining, using the hardware processor, a reward associated with the incorrect
classification made by the predictive model, wherein the reward is directly proportional to the confidence value associated
with the classification of the received instance;

updating, using the hardware processor, the predictive model using the received instance as training data; and
causing, using the hardware processor, an indication of the reward to be provided to the user.
US Pat. No. 9,272,017

PHARMACEUTICAL COMPOSITIONS INCLUDING A PORTION OF THE C-TERMINUS OF FGF23

New York University, New...

1. A pharmaceutical composition comprising:
a peptide comprising at least a portion corresponding to the C-terminus of FGF23, wherein the portion corresponding to the
C-terminus of FGF23 consists of the amino acid sequence of SEQ ID NO:12 and

an additive, wherein the additive is a vitamin D receptor agonist and is formulated in combination with said peptide for simultaneous
administration.

US Pat. No. 9,221,871

METHODS FOR PREPARING INTERNALLY CONSTRAINED PEPTIDES AND PEPTIDOMIMETICS

New York University, New...

1. A method of preparing a compound of Formula II:
wherein
R is hydrogen, an amino acid side chain, an alkyl group, or an aryl group;
R1 is an amino acid side chain, an alkyl group, or an aryl group;

R2 is an amino acid, peptide, OR, CH2NH2, an alkyl group, an aryl group, or a group of Formula:


 wherein R7 is an amino acid, peptide, OR, CH2NH2, an alkyl group, or an aryl group;

is a single or double carbon-carbon bond; is a single bond and is cis or trans when is a double bond; n is 1 or 2; and m is any number,said method comprising:
providing a compound of Formula III or a salt thereof:
wherein R4 is a carboxyl protecting group and
reacting said compound of Formula III or a salt thereof with a peptide coupling reagent of Formula III?:
under conditions effective to produce a compound of Formula II.

US Pat. No. 9,289,566

SYSTEM AND METHOD FOR AUTOMATED TITRATION OF CONTINUOUS POSITIVE AIRWAY PRESSURE USING AN OBSTRUCTION INDEX

NEW YORK UNIVERSITY, New...

1. A system, comprising:
an air pressure supply arrangement providing air pressure to a patient's airways;
a sensor detecting input data corresponding to a patient's breathing patterns of a plurality of breaths; and
a titration device receiving and analyzing the input data to determine existence of breathing disorder and corresponding characteristics,
the titration device generating output data for adjusting the air pressure supplied to the patient as a function of an index
of abnormal respiratory events included in the input data, wherein the index includes a number of the abnormal respiratory
events in a time period.

US Pat. No. 9,139,643

IMMUNOTHERAPY FOR CLEARING PATHOLOGICAL TAU CONFORMERS

New York University, New...

1. A method for treating Alzheimer's disease or other tauopathy in a subject, said method comprising:
administering to said subject an isolated antibody or binding portion thereof that is capable of specifically binding to a
misfolded and/or aggregate form of Tau protein and does not bind to normal Tau protein, wherein said antibody binds an epitope
that is present within amino acid residues 379-408 (SEQ ID NO:2) of said misfolded and/or aggregate form of Tau protein and
is capable of specifically binding to a polypeptide fragment of Tau protein consisting of Tau 379-408 (SEQ ID NO:2);

wherein such antibody was produced by immunization with a polypeptide fragment of Tau consisting of Tau 379-408 (SEQ ID NO:2);
and

wherein said administered antibody or binding portion thereof binds to a misfolded and/or aggregate form of Tau protein of
said subject, and is provided to said subject at a therapeutically-effective dose effective to treat said Alzheimer's disease
or said other tauopathy.

US Pat. No. 9,138,433

INDOLE ALKALOID COMPOUNDS AS MELANOGENESIS PROMOTERS AND USES THEREOF

NEW YORK UNIVERSITY, New...

1. A method for increasing the melanin content in a mammalian subject in need thereof, comprising administering to said mammal
a melanin content-increasing amount of i) an indole alkaloid compound; or ii) a plant extract containing pubescine;
wherein the indole alkaloid compound is according to formula I:

wherein
X is O or CR5;

R1 is selected from the group consisting of hydrogen, hydroxy, substituted or unsubstituted (C1-C6) alkyl, and substituted or unsubstituted (C1-C6) alkoxy;

R2 is selected from the group consisting of hydrogen, hydroxy, substituted or unsubstituted (C1-C6) alkyl, substituted or unsubstituted acyloxy, and substituted or unsubstituted (C1-C6) alkoxy;

R3 is selected from the group consisting of hydrogen, hydroxy, substituted or unsubstituted (C1-C6) alkyl, substituted or unsubstituted acyloxy, substituted or unsubstituted (C1-C6) alkoxy, carboxy, substituted or unsubstituted alkoxycarbonyl, and substituted or unsubstituted amido;

R4 is selected from the group consisting of hydroxy, substituted or unsubstituted (C1-C6) alkyl, substituted or unsubstituted (C1-C6) alkoxy, and halo;

R5 is selected from the group consisting of hydrogen, hydroxy, substituted or unsubstituted (C1-C6) alkyl, substituted or unsubstituted acyloxy, substituted or unsubstituted (C1-C6) alkoxy;

n is 0, 1, 2, 3, or 4; and the dotted bond is a single or a double bond;
or pharmaceutically acceptable salts, solvates, stereo isomers, tautomers, isotopic variants or prodrugs thereof.

US Pat. No. 9,067,069

COCHLEAR IMPLANT FITTING SYSTEM

NEW YORK UNIVERSITY, New...

1. A method, comprising:
displaying a visual representation of a plurality of frequency-to-electrode maps for selection by a user, the visual representation
configured to facilitate a comparison between patient responses to auditory stimulation having parameters corresponding to
each of the frequency-to-electrode maps;

providing a first auditory stimulation to a first ear of a patient having a first cochlear implant, wherein parameters of
the first auditory stimulation correspond to a first frequency-to-electrode map selected by the user using the visual representation,
and the first auditory stimulation is electrical;

obtaining from the patient, in real-time, ratings corresponding to hearing percepts of the patient in response to the first
selected frequency-to-electrode map; and

adjusting, within an interstimulus interval of 2 seconds or less, the parameters of the first auditory stimulation to the
first ear to correspond to a second frequency-to-electrode map selected by the user using the visual representation.

US Pat. No. 9,329,414

METHODS USING AN INTENSE CONTROL LIGHT AT A FIRST WAVELENGTH TO CAUSE A WHISPERING GALLERY MODE RESONATOR TO SELF TUNE AT A SECOND WAVELENGTH, AND APPARATUS EMPLOYING SUCH METHODS SUCH AS OPTICAL PASS/STOP BAND FILTERS AND OPTICAL

Polytechnic Institute of ...

1. A method comprising:
a) optically coupling light of at least a predetermined intensity, at a first wavelength, with a whispering gallery mode (WGM)
resonator of a WGM-based optical filter to cause the WGM resonator to self tune to a desired pass band of the WGM-based optical
filter; and

b) receiving, with the WGM resonator of the WGM-based optical filter, an optical signal at a second wavelength within the
pass band, wherein the second wavelength is different from the first wavelength.

US Pat. No. 9,329,182

METHOD OF TREATING MOTOR NEURON DISEASE WITH AN ANTIBODY THAT AGONIZES MUSK

New York University, New...

1. A method for delaying motor dysfunction in a subject suffering from amyotrophic lateral sclerosis (ALS), the method comprising
the steps of: selecting the subject suffering from ALS and administering an agent that increases muscle specific receptor
kinase (MuSK) activity to the subject in a therapeutically effective amount sufficient to increase MuSK activity in the subject,
wherein the agent is an antibody or antibody fragment that increases MuSK activity upon binding to MuSK, thereby improving
motor function in the subject.
US Pat. No. 9,295,719

METHOD FOR TREATING AMYLOID DISEASE

NEW YORK UNIVERSITY, New...

1. A method for treating a patient suffering from an amyloid disease or a tauopathy comprising administering to the patient
a therapeutically effective amount of a polymerized form of an immunogenic modified A? peptide, which peptide contains Lysine
substitutions in amino acid positions corresponding to amino acids 18 and 19 of A?1-42, which polymerized form is soluble,
non-fibrillogenic, has molecular weight less than 100 kDa, has the property of eliciting antibodies directed against the abnormal
conformation of A? in amyloid plaques and/or in soluble and semi-soluble A? oligomers, and is produced using controlled polymerization
of peptide monomers with glutaraldehyde.

US Pat. No. 9,265,735

METHODS FOR SCREENING TO IDENTIFY THERAPEUTIC AGENTS FOR ALZHEIMER'S DISEASE AND USE THEREOF

New York University, New...

1. A method for treating a subject with Alzheimer's Disease (AD), wherein the subject has impaired lysosomal activity, the
method comprising providing a subject with AD and reduced lysosomal activity and administering to the subject an agent that
enhances lysosomal activity, wherein the agent is a ?-adrenergic agonist.

US Pat. No. 9,812,184

CURRENT INDUCED SPIN-MOMENTUM TRANSFER STACK WITH DUAL INSULATING LAYERS

NEW YORK UNIVERSITY, New...

1. A magnetic device comprising:
a pinned magnetic layer with a magnetization vector having a fixed magnetization direction at a non-zero acute angle relative
to a normal of a plane of the pinned magnetic layer;

a free magnetic layer with at least one magnetization vector having a changeable magnetization direction, wherein the magnetization
vector of the free magnetic layer has at least a first stable state and a second stable state, and wherein the first and second
stable states both have magnetization directions that are perpendicular to a plane of the free magnetic layer; and

a nonmagnetic layer spatially separating the pinned magnetic layer and the free magnetic layer, wherein application of a current
pulse of sufficient amplitude and duration through the magnetic device switches the magnetization vector of the free magnetic
layer between the first and second stable states.

US Pat. No. 9,458,449

HYBRID POLYMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF SYNTHESIZING THE SAME

New York University, New...

1. A hybrid polymer comprising an abiotic oligomer segment and a polypeptide segment; and wherein the polypeptide segment
comprises at least one serine or threonine residue at its N-terminus, and the abiotic oligomer segment is bonded to the polypeptide
through the serine or the threonine residue; and wherein
the said abiotic oligomer segment comprises N-substituted glycine peptoid oligomers, beta-peptoids, beta-peptides, alternating
alpha/beta peptides, gamma-peptides, pyridine oligoamides, quinoline oligoamides, aryl oligoamides, aedemers, peptide nucleic
acids, other abiotic oligoamides, sulfonamidopeptides, aminoxy acid oligomers, hydrazone-linked pyrimidines, oligo-ureidophthalimides,
triazine-based oligomers, triazole-based oligomers, oligooxopiperazine oligomers, and oligoureas or any combinations thereof;

provided that the hybrid polymer is other than HP1, HP2, HP3, HP4, HP5, or HP6.

US Pat. No. 9,376,469

PROTEOLYTICALLY RESISTANT HYDROGEN BOND SURROGATE HELICES

New York University, New...

1. A peptidomimetic having a stable, internally constrained protein secondary structure, wherein the peptidomimetic is a compound
of Formula I:
wherein:
B is C(R1)(R1?), O, S, or NR1;

is a double bond and each R1? is absent; or is a single bond and each R1? is independently hydrogen, an amino acid side chain, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a heterocyclyl, an aryl,
a heteroaryl, or an arylalkyl;

each R1 is independently hydrogen, an amino acid side chain, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a heterocyclyl, an aryl,
a heteroaryl, or an arylalkyl;

R2 is hydrogen; an alkyl; an alkenyl; an alkynyl; a cycloalkyl; a heterocyclyl; an aryl; a heteroaryl; an arylalkyl; an alpha
amino acid; a beta amino acid; a peptide; a targeting moiety; a tag; —OR5 wherein R5 is hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a heterocyclyl, an aryl, a heteroaryl, an arylalkyl, an acyl,
a peptide, a targeting moiety, or a tag; —(CH2)0-1N(R5)2 wherein each R5 is independently hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a heterocyclyl, an aryl, a heteroaryl, an arylalkyl,
an acyl, a peptide, a targeting moiety, or a tag; or a moiety of Formula A:


wherein:
R2? is hydrogen; an alkyl; an alkenyl; an alkynyl; a cycloalkyl; a heterocyclyl; an aryl; a heteroaryl; an arylalkyl; an alpha
amino acid; a beta amino acid; a peptide; a targeting moiety; a tag; —OR5 wherein R5 is hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a heterocyclyl, an aryl, a heteroaryl, an arylalkyl, an acyl,
a peptide, a targeting moiety, or a tag; or —(CH2)0-1N(R5)2 wherein each R5 is independently hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a heterocyclyl, an aryl, a heteroaryl, an arylalkyl,
an acyl, a peptide, a targeting moiety, or a tag;

m? is zero or any number;
each b is independently one or two; and
c is one or two;
R3 is hydrogen; an alkyl; an alkenyl; an alkynyl; a cycloalkyl; a heterocyclyl; an aryl; a heteroaryl; an arylalkyl; an alpha
amino acid; a beta amino acid; a peptide; a targeting moiety; a tag; —OR5 wherein R5 is hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a heterocyclyl, an aryl, a heteroaryl, an arylalkyl, an acyl,
a peptide, a targeting moiety, or a tag; —N(R5)2 wherein each R5 is independently hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a heterocyclyl, an aryl, a heteroaryl, an arylalkyl,
an acyl, a peptide, a targeting moiety, or a tag; or a moiety of Formula B:


wherein:
R3? is hydrogen; an alkyl; an alkenyl; an alkynyl; a cycloalkyl; a heterocyclyl; an aryl; a heteroaryl; an arylalkyl; an alpha
amino acid; a beta amino acid; a peptide; a targeting moiety; a tag; —OR5 wherein R5 is hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a heterocyclyl, an aryl, a heteroaryl, an arylalkyl, an acyl,
a peptide, a targeting moiety, or a tag; or —N(R5)2 wherein each R5 is independently hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a heterocyclyl, an aryl, a heteroaryl, an arylalkyl,
an acyl, a peptide, a targeting moiety, or a tag;

m? is zero or any number; and
each d is independently one or two;
each R4 is independently hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a heterocyclyl, an aryl, a heteroaryl, or an arylalkyl;

m, n?, and n? are each independently zero, one, two, three, or four, wherein the sum of m, n?, and n? is from two to six;
m?? is zero or one;
a is one or two;
each o is independently one or two;
p is one or two; and
wherein at least one of the following conditions is met
(i) m is one, two, three, or four and at least one o is two;
(ii) p is two;
(iii) m?? is one and a is two;
(iv) R2 is a beta amino acid;

(v) R2 is a moiety of Formula A wherein m? is at least one and at least one b is two;

(vi) R2 is a moiety of Formula A wherein c is two;

(vii) R2 is a moiety of Formula A wherein R2? is a beta amino acid;

(viii) R3 is a beta amino acid;

(ix) R3 is a moiety of Formula B wherein m? is at least one and at least one d is two; and

(x) R3 is a moiety of Formula B wherein R3? is a beta amino acid.

US Pat. No. 9,296,688

CARBOHYDRATE-SELECTIVE RECEPTORS

New York University, New...

1. A compound of Formula I:

R is a moiety of Formula II
or a moiety of Formula III

is a single or a double bond;
A is selected from the group consisting of: (1) —CH2—; (2) —C(O)—; and 3) ?CH—;

B is H, and n is 0 or 1;
each of R1, R2, R3, and R4 is a heterocycle or a heteroaryl containing 1-5 heteroatoms selected from the group consisting of nitrogen, sulfur, and oxygen,
wherein R1, R2, R3, and R4 can be the same or different;

R1, R2, R3, and R4 can be optionally substituted 1 to 4 times with substituents selected from the group consisting of halogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, aryl, —OR5, —CN, —NO2, —NR5R6, —COOR5, —COR5, —CONHR5, and —CN;

and
each of R5 and R6 is independently H or C1-6 alkyl.

US Pat. No. 9,188,529

HOLOGRAPHIC MICROREFRACTOMETER FOR DETERMINING REFRACTIVE INDEX OF A MEDIUM

NEW YORK UNIVERSITY, New...

1. A method for determining refractive index at a plurality of points in a medium, comprising the steps of:
providing a source of light for generating a collimated beam of coherent light;
providing an optical microscope having a focal plane;
providing a fluid medium whose refractive index is to be determined;
providing a refractive index probe comprised of at least one probe particle disposed in the medium;
inputting the coherent light to the optical microscope and illuminating the at least one probe particle disposed in the medium;
forming an interference pattern in the focal plane from light scattered by the at least one probe particle and an unscattered
portion of the collimated beam;

recording the interference pattern; and
analyzing the interference pattern and fitting the pattern to obtain the refractive index of the medium in the focal plane
of the refractive index probe in the medium.

US Pat. No. 9,563,101

COMMON-PATH NONCOLLINEAR OPTICAL PARAMETRIC AMPLIFIER

New York University, New...

1. An optical parametric amplifier comprising:
a light source;
a phase-stable optical splitter selected from the group consisting of a phase mask and a Wollaston prism, the phase-stable
optical splitter configured to receive light from the light source and split the received light into a first beam and a second
beam;

first beam optics in optical communication with the phase-stable optical splitter for receiving the first beam;
second beam optics in optical communication with the phase-stable optical splitter for receiving the second beam; and
common path reflective elements positioned relative to the first beam optics and the second beam optics for receiving and
redirecting light from the first beam optics and the second beam optics.

US Pat. No. 9,254,274

METHOD OF TREATING TOURETTE'S DISORDER WITH GABA-AMINOTRANSFERASE INACTIVATORS

Catalyst Pharmaceutical P...

1. A method of treating Tourettes Disorder (TD) comprising elevating the build-up of GABA in presynaptic terminals of GABA-ergic
neurons.
US Pat. No. 9,109,225

ENGINEERED TRANSPOSON FOR FACILE CONSTRUCTION OF A RANDOM PROTEIN DOMAIN INSERTION LIBRARY

New York University, New...

1. A method for facile construction of a random domain insertion library comprising the steps of:
providing an engineered transposon;
randomly transposing the engineered transposon into a host DNA sequence, using plasmid PUC19 containing lacZ? as the host
DNA sequence;

employing sticky-end ligation between the host DNA sequence and a guest DNA sequence, using a gene coding for xylanase from
bacillus circulans (BCX) as the guest DNA sequence; and

removing the engineered transposon from the host DNA sequence by restriction enzyme digestion, wherein the restriction enzyme
digestion is double digestion using BclI and AgeI restriction enzymes,

thereby generating a plasmid for the domain insertion library.
US Pat. No. 9,095,550

METHODS FOR TREATING DIABETIC WOUNDS

NEW YORK UNIVERSITY, New...

1. A method for treating a chronic wound of a mammal, which comprises topically administering to the wound a therapeutically
effective amount of a functional fragment of a mammalian calreticulin, wherein the functional fragment is the N-, P- or C-domain
of a mammalian calreticulin.

US Pat. No. 9,094,350

FINDING NONEQUIVALENT CLASSIFIERS TO REDUCE TERNARY CONTENT ADDRESSABLE MEMORY (TCAM) USAGE

Polytechnic Institute of ...

1. A computer-implemented method for providing an efficient physical implementation of a first classifier defined by a first
rule set, at least a part of which first classifier having a sparse distribution in Boolean space, the computer-implemented
method comprising:
a) converting the first classifier, having a corresponding Boolean space, into a second classifier, wherein the second classifier
has a corresponding Boolean space which is not semantically equivalent to the Boolean space corresponding to the first classifier,
and wherein the second classifier is defined by a second set of rules which is smaller than the first set of rules defining
the first classifier;

b) storing a data structure representing the second classifier; and
c) configuring a bit string transformation component to transform a first bit string into a second bit string, wherein applying
the first bit string to the first classifier is equivalent to applying the second bit string to the second classifier.

US Pat. No. 9,062,122

TARGETING THE ROSA26 GENE IN HUMAN EMBRYONIC STEM CELLS

MOUNT SINAI SCHOOL OF MED...

1. A method for modifying a human Rosa26 gene in an isolated human embryonic stem cell, which method comprises introducing
exogenous DNA into the human Rosa26 gene in an isolated human embryonic stem cell.

US Pat. No. 9,683,039

NOTCH AGONISTS FOR THE TREATMENT OF CANCER

New York University, New...

1. A method of inducing cell differentiation and cell death in a population of acute myeloid leukemia leukemia-initiating
cells (LICs), said method comprising:
administering a Notch receptor agonist to the population of acute myeloid leukemia LICs under conditions effective to induce
cell differentiation and cell death in the population of acute myeloid leukemia LICs.

US Pat. No. 9,433,611

OXAZOLE AND THIAZOLE COMPOUNDS AS ?-CATENIN MODULATORS AND USES THEREOF

New York University, New...

1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of
a compound according to formula I:

wherein A is A1;

A1 is


x is 1;
L1 is S, SO or SO2;

m1 is 1, 2 or 3; n is 1, 2, 3, 4 or 5;
each R1, R2a, R2b, R2c, and R2d is independently selected from hydrogen, halo, and substituted or unsubstituted C1-C6 alkyl;

R3 is NR3aR3b; and

one of R3a and R3b is substituted or unsubstituted alkyl, substituted or unsubstituted benzyl, substituted or unsubstituted phenethyl, cycloheptyl,
cyclohexyl, cyclohexyl substituted with methyl or dimethyl, substituted or unsubstituted cyclopentyl, substituted or unsubstituted
cyclobutyl, or substituted or unsubstituted cyclopropyl; and the other is H or substituted or unsubstituted alkyl; or

NR3aR3b is:


and wherein R3c is H or alkyl;

each R4 is independently selected from alkyl, substituted alkyl, acyl, substituted acyl, substituted or unsubstituted acylamino, substituted
or unsubstituted alkylamino, substituted or unsubstituted alkythio, substituted or unsubstituted alkoxy, alkoxycarbonyl, substituted
alkoxycarbonyl, substituted or unsubstituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted
aryl, arylalkyl, substituted or unsubstituted sulfonyl, substituted or unsubstituted sulfinyl, substituted or unsubstituted
sulfanyl, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted arylsulfonyl, azido, carboxy, substituted
or unsubstituted carbamoyl, cyano, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloheteroalkyl,
substituted or unsubstituted dialkylamino, heteroaryloxy, substituted or unsubstituted heteroaryl, substituted or unsubstituted
heteroalkyl, hydroxy, nitro, and thiol; and

a pharmaceutically acceptable salt, solvate or prodrug thereof;
and stereoisomers, isotopic variants and tautomers thereof.

US Pat. No. 9,418,644

PITCH DETECTION

New York University, New...

1. A string vibration pickup device comprising:
a sensor configured to engage a string to detect vibrations;
a pickup base having a pickup in communication with the sensor to receive electrical signals indicative of sensed vibrations
for the string; and

an enclosure connected to the pickup base, the enclosure comprising a first arm and second arm, the first arm and second arm
at least partially nestable relative to each other such that the width of the enclosure is adjustable.

US Pat. No. 9,390,163

METHOD, SYSTEM AND SOFTWARE ARRANGEMENT FOR DETECTING OR DETERMINING SIMILARITY REGIONS BETWEEN DATASETS

New York University, New...

1. A method for obtaining information associated with a sequence similarity across a plurality of regions among a plurality
of strings, comprising:
(a) receiving a particular string and at least one further string, wherein at least one of the particular string or the at
least one further string is ordered;

(b) organizing the particular string into the regions;
(c) generating a plurality of subregions corresponding to a sample of the regions;
(d) obtaining particular information related to at least one of an initially unknown or guessed-at predetermined statistical
distribution of local variations in the sequence similarity;

(e) using a processing arrangement, automatically determining local variations in the sequence similarity across the subregions
with respect to the at least one further string based on the particular information;

(f) using the processing arrangement, modifying the particular information based on the determined local variations in sequence
similarity;

(g) repeating procedures (e) and (f) until a preselected criterion is met; and
(h) at least one of storing the particular information in a storage arrangement in at least one of a user-accessible format
or a user-readable format or displaying the particular information on a hardware display,

wherein the particular information is provided in a form of a sequence similarity curve that includes a highest similarity
of a particular subregion of the subregions at a particular position in the particular string compared to a further subregion
of all positions in the at least one further string, and wherein a computational time utilized to perform procedures (e) to
(g) is linearly proportional to a size of at least one of the particular string or the at least one further string.

US Pat. No. 9,243,275

BIOSENSOR AND METHOD OF MAKING SAME

Polytechnic Institute of ...

1. A sensor fabrication method comprising the steps of:
a) polymerizing a layer of polysiloxane onto a substrate such that it sufficiently adheres thereto,
wherein the substrate is selected from a group consisting of electrodes, diodes, field effect transistors, insulated gate
field effect transistors, and metal oxide semiconductor field effect transistor; and

b) adsorbing heptapeptide ligand selector molecules onto the layer of polysiloxane,
wherein the steps of polymerizing and adsorbing occur concurrently and absent from an electrical voltage or current applied
to the substrate and comprise: immersing the substrate in a solution or a suspension including polysiloxane-forming monomers
and selector molecules, both polysiloxane-forming monomers and selector molecules being dispersed in the bulk of the solution
or suspension, and

wherein the polymerizing step and the adsorbing step hold heptapeptide ligand selector molecules onto the substrate by using
hydrophobic silanol groups of the polysiloxane layer.

US Pat. No. 9,125,897

CANCER TREATMENT WITH ENDOTHELIN RECEPTOR ANTAGONISTS

NEW YORK UNIVERSITY, New...

1. A method for inhibiting the early development of mammary cancer in a patient in need thereof, comprising administering
a therapeutically effective amount of a selective endothelin B receptor ETB antagonist to said patient, with the proviso that
said method does not include gene therapy, wherein said antagonist does not include sRNA, antisense molecules and ribozymes,
and wherein the ability of the selective endothelin B receptor (ETB) antagonist to antagonize the endothelin B receptor (ETB)
is determined in vitro by:
a. contacting a cell culture expressing endothelin B receptor (ETB) and E-cadherin with endothelin and a selective ETB antagonist;
b. determining the level of E-cadherin expression; and
c. comparing the level of E-cadherin expression determined in step b) to that of a control culture in the absence of the selective
ETB antagonist, so that an increase in expression of E-cadherin indicates antagonist activity.

US Pat. No. 9,102,712

DENDRIMERIC PEPTIDES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME

New York University, New...

1. A pharmaceutical composition for treating or managing a disease or condition caused by bacteria; wherein the pharmaceutical
composition comprises a peptide according to formula I:

wherein
L1 is independently unsubstituted C2-5 alkylene;

L2 is unsubstituted C3-5 alkylene;

each R1 is independently

—NH—WR—Z, —NH—RW—Z, —NH—RF—Z, —NH—FR—Z, —NH—RY—Z, —NH—YR—Z, —NH—KW—Z, —NH—WK—Z, —NH—KY—Z, —NH—YK—Z, —NH—KF—Z, —NH—FK—Z, —NH—RWW—Z,
—NH—RFF—Z, —NH—RYY—Z, —NH—KWW—Z, —NH—KYY—Z, —NH—KFF—Z, —NH—WWR—Z, —NH—FFR—Z, —NH—YYR—Z, —NH—WWK—Z, —NH—YYK—Z, or —NH—FFK—Z,

or

m is 1, 2, 3, or 4; each Z is independently H, Ac, or any other conventional N-protecting group;
R3 is unsubstituted alkyl, aralkyl, heteroarylalkyl, aminoalkyl, or guanidinoalkyl;

R2 is R1; or R2 is —N(L1-R1)2;

and
Tta is 2,5,7-trialkyltryptophan residue;
or a pharmaceutically acceptable salt thereof.

US Pat. No. 9,081,071

LONGEVITY OF HYPERPOLARIZED ENHANCED SIGNALS FOR 1H NMR SPECTROSCOPY

New York University, New...

1. A method of providing increased longevity of hyperpolarized 1H NMR signals for NMR spectroscopy and magnetic resonance imaging (MRI), comprising the steps of:
providing a material including a molecular species susceptible of NMR and MRI spectroscopy/imaging;
providing parahydrogen for input to the material; and
inputting the parahydrogen to the material by distributing parahydrogen through the material for a time to establish increased
longevity of the NMR and MRI signals;
adding a surfactant to the material, thereby providing increased persistence of the parahydrogen for the molecular species.

US Pat. No. 9,315,548

PEPTOID OLIGOMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME

New York University, New...

1. A peptoid oligomer according to formula lb:

wherein
each R1 is independently R1a, R1b, or R1c;

each R2 is independently hydrogen, or substituted or unsubstituted alkyl; or each R1 and R2 are joined together to form a 4-7 membered heterocyclic ring;

each R1a is independently unsubstituted alkyl, or alkyl substituted with halo, hydroxy, amino, nitro, or alkoxy;

each R1b is independently aminoalkyl, guanidinoalkyl (H2N—C(?NH)—NH-alkyl), or N-containing heteroarylalkyl, and each R1b is unsubstituted or substituted with one or more F;

each R1c is independently substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, substituted or unsubstituted heteroarylalkyl,
or substituted or unsubstituted diarylalkyl;

and n is an integer between 4 and 20;
provided that at least one of R1s is R1b;

a pharmaceutically acceptable salt, a stereoisomer, an isotopic variant, or a tautomer thereof.

US Pat. No. 9,261,514

CONFORMATIONAL-SWITCHING FLUORESCENT PROTEIN PROBE FOR DETECTION OF ALPHA SYNUCLEIN OLIGOMERS

New York University, Bro...


US Pat. No. 9,173,871

OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF

New York University, New...

1. A method for treating or ameliorating in a mammal a disease or condition that is causally related to the aberrant activity
of the Wnt signaling pathway in vivo, wherein the disease or condition is a cancer, which method comprises administering to
the mammal an effective disease-treating or condition-treating amount of a compound according to formula I:

wherein A is A1;

A1 is


x is 1;
L1 is S, SO or SO2;

m1 is 1, 2 or 3; n is 1, 2, 3, 4 or 5;
each R1, R2a, R2b, R2c, and R2d is independently selected from hydrogen, halo, and substituted or unsubstituted C1-C6 alkyl;

R3 is hydroxy, alkoxy, substituted or unsubstituted amino or cycloheteroalkyl;

each R4 is independently selected from H, alkyl, substituted alkyl, acyl, substituted acyl, substituted or unsubstituted acylamino,
substituted or unsubstituted alkylamino, substituted or unsubstituted alkythio, substituted or unsubstituted alkoxy, alkoxycarbonyl,
substituted alkoxycarbonyl, substituted or unsubstituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl,
substituted aryl, arylalkyl, substituted or unsubstituted sulfonyl, substituted or unsubstituted sulfinyl, substituted or
unsubstituted sulfanyl, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted arylsulfonyl, azido, carboxy,
substituted or unsubstituted carbamoyl, cyano, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloheteroalkyl,
substituted or unsubstituted dialkylamino, halo, heteroaryloxy, substituted or unsubstituted heteroaryl, substituted or unsubstituted
heteroalkyl, hydroxy, nitro, and thiol;

or a pharmaceutically acceptable salt, solvate or prodrug thereof;
and stereoisomers, isotopic variants and tautomers thereof.

US Pat. No. 9,147,059

BIOMETRIC-RICH GESTURES FOR AUTHENTICATION ON MULTI-TOUCH DEVICES

Polytechnic Institute of ...

1. A computer-implemented method comprising:
a) obtaining, by a computer system including one or more processors, a multi-touch input sequence including
1) determining, at a plurality of time instances, a mapping from an unordered set of at least four touch points to an ordered
set of at least four fingertips, wherein for at least one of the plurality of time instances, the mapping from the unordered
set of at least four touch points to the ordered set of at least four fingertips is subject to a constraint that the ordered
set of at least four touch points defines a simple polygon; and

b) controlling, by the computer system, access to a device, service, or information, using the obtained multi-touch input
sequence.

US Pat. No. 9,132,145

COMPOSITIONS AND METHODS FOR TREATING OBESITY, OBESITY RELATED DISORDERS AND FOR INHIBITING THE INFECTIVITY OF HUMAN IMMUNODEFICIENCY VIRUS

New York University, New...

1. A method for treating a human suffering from obesity comprising administering to said human suffering from obesity a therapeutically
effective amount of a purified oleuropein to treat said obesity in the human.

US Pat. No. 9,081,991

RING OSCILLATOR BASED DESIGN-FOR-TRUST

Polytechnic Institute of ...

1. A computer-implemented method for enabling detection of a Trojan in an integrated circuit (IC), the computer-implemented
method comprising:
a) selecting a path in the IC based on a path selection criteria, wherein the path has one or more unsecured gates;
b) embedding a ring oscillator on the IC to secure the one or more unsecured gates in the selected path, wherein the selected
path is a functional path of the IC, and wherein the selected path defines a portion of the embedded ring oscillator;

c) determining an input pattern to be provided to the IC, to activate the embedded ring oscillator;
d) repeating acts (a)-(c) until a stop condition is met; and
e) determining a golden frequency of each of one or more of the embedded ring oscillators, wherein the golden frequency is
a frequency at which the embedded ring oscillator oscillates without a presence of the Trojan.

US Pat. No. 9,519,348

HAPTIC FORCE-FEEDBACK FOR COMPUTING INTERFACES

New York University, New...

1. A haptic device comprising:
a housing;
an actuation mechanical structure having:
a ball partially disposed within the housing and rotatable thereto with a portion extending beyond the housing;
a first motor and an associated first drive train in communication with the ball for rotating the ball about a x-axis, a first
motor first drive gear, a first motor second drive gear perpendicular to the first motor first drive gear, and a first motor
drive wheel for engaging the ball;

a second motor and an associated second drive train in communication with the ball for rotating the ball about a y-axis that
is perpendicular to the x-axis, a second motor first drive gear, a second motor second drive gear perpendicular to the second
motor first drive gear, and a second motor drive wheel for engaging the ball;

a gyroscope;
a microcontroller in communication with a memory module, a communication module, the first motor and the second motor, and
a power module;

wherein at least one of direction of rotation and torque of the ball are selected based upon a factor selected from the group
consisting of a selected color corresponding to a display on the graphical user interface and a determined position of the
haptic device relative to an object displayed on the graphical user interface.

US Pat. No. 9,455,996

GENERATING PROGRESSIVELY A PERFECT HASH DATA STRUCTURE, SUCH AS A MULTI-DIMENSIONAL PERFECT HASH DATA STRUCTURE, AND USING THE GENERATED DATA STRUCTURE FOR HIGH-SPEED STRING MATCHING

New York University, New...

1. A method for performing multi-string matching in a network system including at least one of a microprocessor, a field programmable
gate array, or an application specific integrated circuit, method comprising:
a) placing transitions, each transition being from a source state to a destination state and associated with an input character,
of an automaton into a hash table data structure stored on a non-transitory storage device to generate a perfect hash table,
by:

1) dividing, using the network system, the transitions into multiple independent sets according to their respective source
states;

2) ordering, using the network system, the sets of transitions based on the number of transitions belonging to the set, thereby
defining an order of the sets from a set of transitions having a largest number of transitions among the sets of transitions
to a set of transitions having a smallest number of transitions among the sets of transitions; and

3) constructing, using the network system, a perfect hash table by, for each of the sets of transitions, in the order from
the set of transitions having the largest number of transitions to the set of transitions having the smallest number of transitions,
hashing the transitions of the set into the hash table data structure to generate a perfect hash table stored in memory;

b) receiving by the network system, input character information;
c) concatenating by the network system, the input character information with a current state of the automaton to generate
concatenated information defining a lookup key;

d) hashing by the network system, the concatenated information to generate an index to the perfect hash table;
e) reading an entry of the perfect hash table using the index;
f) comparing the lookup key with information in a first part of the entry of the perfect hash table read; and
g) responsive to a determination that the lookup key matches the information in the first part of the entry of the perfect
hash table, using information in a second part of the entry to (1) update the current state of the automaton, and (2) find
any matched rules.

US Pat. No. 9,408,887

INTERMITTENT DOSING REGIMEN FOR TREATING BREAST CANCER

New York University, New...

1. A method for treating breast cancer in a mammal, the method comprising administering at least one inhibitor of insulin-like
growth factor I (IGF-I) activity to the mammal, wherein the at least one inhibitor is SOM230 or pasireotide/SOM230 long acting
release (pasireotide LAR) and is administered in accordance with an intermittent dosing regimen whereby treatment periods
are interrupted by rest periods wherein the at least one inhibitor of IGF-I activity is not administered to the mammal, and
the rest periods permit recovery from side effects due to administration of the at least one inhibitor of IGF-I activity.

US Pat. No. 9,272,105

SYSTEM AND METHOD FOR DIAGNOSIS AND TREATMENT OF OBSTRUCTIVE SLEEP APNEA

NEW YORK UNIVERSITY, New...

1. A system for diagnosis and treatment of breathing disorders in a patient, comprising:
a flow generator supplying an airflow to an airway of a patient via an air flow path;
a venting arrangement moveable between (i) a closed position in which the flow path is substantially sealed from an ambient
atmosphere between the flow generator and the patient's airway, and (ii) an open position in which the flow path is open to
the ambient atmosphere;

a sensor detecting data corresponding to flow through the patient's airway; and
a processing arrangement controlling operation of the venting arrangement and the flow generator,
wherein, in a diagnostic mode, the processing arrangement maintains the venting arrangement in the open position and monitors
airflow through the patient's airway using the data provided by the sensor, and

wherein, in a therapeutic mode, the processing arrangement maintains the venting arrangement in the closed position and controls
the flow generator to supply to the patient's airway via the flow path a therapeutic pressure calculated based on the data
compiled in the diagnostic mode.

US Pat. No. 9,206,180

SUPERSTRUCTURES OF DIKETOPYRROLOPYRROLE DONORS AND PERYLENEDIIMIDE ACCEPTORS FORMED BY HYDROGEN-BONDING AND ?•••? STACKING

New York University, New...

1. A self-assemblying composition comprising:
a plurality of diketopyrrolepyrrole donors having at least two solubilizing alkyl side chains (R1); and
a plurality of perylenediimide acceptors;
wherein each of the plurality of diketopyrrolepyrrole donors triple hydrogen-bonds along a first spatial axis (x) with one
of the plurality of perylenediimide acceptors and each of the plurality of diketopyrrolepyrrole donors interacts with another
of the plurality of diketopyrrolepyrrole donors via ?•••? stacking along a second spatial axis (z) orthogonal to the first
spatial axis (x), each of the plurality of perylenediimide acceptors interacts with another of the plurality of perylenediimide
acceptors via ?•••? stacking along the second spatial axis (z) orthogonal to the first spatial axis (x),and the solubilizing
alkyl chains extending along a third spatial axis (y) orthogonal to the first spatial axis and the second spatial axis.

US Pat. No. 9,201,152

SEISMIC PREDICTION WITH DECAY PRODUCTS

NEW YORK UNIVERSITY, New...

1. An method for predicting seismic activity, comprising:
determining a current amount of unattached 218Po; and

comparing the amount of unattached 218Po to a baseline of unattached elements selected from the group consisting of 218Po, 214Pb? and 214Bi.

US Pat. No. 9,810,894

TRACKING AND CHARACTERIZING PARTICLES WITH HOLOGRAPHIC VIDEO MICROSCOPY

NEW YORK UNIVERSITY, New...

11. A computer implemented system comprising:
a holographic microscope apparatus comprising a coherent light source with multiple discrete concurrent wavelengths of coherent
light beams' a specimen stage, an objective lens, and an image collection device;

a computer module in communication with the holographic microscope apparatus and including a processor and memory, the memory
receiving image data from the image collection device and further having a set of instructions for;

selecting multiple wavelengths for a laser;
scattering the laser's beam off the specimen to generate a scattered portion;
generating an interference pattern from an unscattered portion of the collimated laser beam and the scattered portion;
recording the interference pattern for subsequent analysis;
applying a scattering function to analyze the recorded interference pattern wherein the scattering function comprises a Lorenz-Mie
function;

normalizing the interference pattern by dividing the interference pattern by a background form of interference pattern;
fitting a calculated hologram to the interference pattern; and
determining an estimate of the specimen's refractive index and radius from the fitted calculated hologram;
wherein the determining of the refractive index of the specimen comprises measuring refractive indices of the specimen at
each of the multiple wavelengths.

US Pat. No. 9,649,201

ANATOMIC SOCKET ALIGNMENT GUIDE AND METHODS OF MAKING AND USING SAME

NEW YORK UNIVERSITY, New...

1. An orthopedic device set comprising:
a positioning guide having:
a first surface substantially conforming to a patient's native acetabulum; and
a second surface distal to the first surface, the second surface substantially conforming to a region of the patient's native
pelvis and comprising one or more apertures therethrough defining positioning guide reference locations; and

an insertion guide having:
a first surface comprising one or more securing features positioned such that the securing features are equidistant relative
to the positioning guide second surface reference locations;

a second surface distal to the first surface, the second surface having an aperture therethrough, the aperture being offset
from the securing features by a patient-specific distance such that the aperture aligns centrally with the acetabulum of the
patient; and

a third surface located distal to the aperture of the second surface at a distance defined by the radius of an acetabular
socket prosthesis, the third surface further comprising an annular depression of sufficient size and depth to engage removably
a portion of the acetabular socket prosthesis.

US Pat. No. 9,672,601

SYSTEM, METHOD AND COMPUTER-ACCESSIBLE MEDIUM FOR RESTORING AN IMAGE TAKEN THROUGH A WINDOW

New York University, New...

1. A non-transitory computer-accessible medium having stored thereon computer-executable instructions for modifying at least
one image, wherein, when a computer hardware arrangement executes the instructions, the computer arrangement is configured
to perform procedures comprising:
receiving first image information for the at least one image;
generating second image information by separating the first image information into at least two overlapping images; and
modifying the at least one image using a prediction procedure based on the second image information
wherein the prediction procedure is associated with at least one convolutional neural network that receives each of the overlapping
images as an input.

US Pat. No. 9,618,840

SYSTEMS AND METHODS FOR POLYMER TIPS USING SILANATED SUPPORTS

NEW YORK UNIVERSITY, New...

1. A method of synthesizing tips for polymer pen lithography comprising:
silanating a support structure comprising a glass material;
selecting a polymer selected from the group consisting of methacrylates, acrylates, elastomers, thiol-ene polymers and co-polymers
thereof;

depositing the selected polymer into molds;
covering the molds with the glass support structure, the polymer adhering to the support structure; and
removing the support structure and tips which comprise the selected polymer from the molds;
wherein silanating is done prior to covering the molds and comprises:
immersing the glass support structure in an acid bath;
removing the glass support structure from the acid bath;
drying the glass support structure with an inert gas;
placing the dried glass support structure in an organic silane solution comprising 3-methacryloxypropyltrimethoxysilane (MEMO)
and toluene.

US Pat. No. 9,464,126

CHIMERIC FIBROBLAST GROWTH FACTOR 21 PROTEINS AND METHODS OF USE

New York University, New...

1. A chimeric protein comprising:
an N-terminus coupled to a C-terminus,
wherein the N-terminus comprises an FGF2 portion beginning at any one of residues 1 to 25 and ending at any one of residues
151-155 of SEQ ID NO: 121,

wherein the FGF2 amino acid positions corresponding to those selected from the group consisting of N36, K128, R129, K134,
K138, Q143, K144, and combinations thereof are substituted to decrease binding affinity for heparin and/or heparan sulfate
compared to FGF2 without the substitution, and

wherein the C-terminus comprises a portion of an FGF21 comprising amino acid residues 168 to 209 of SEQ ID NO:233.
US Pat. No. 9,410,205

METHODS FOR PREDICTING SURVIVAL IN METASTATIC MELANOMA PATIENTS

New York University, New...

1. A method for treating a mammal with Stage IIIB or Stage IIIC melanoma, said method comprising: a) isolating a melanoma
sample from the mammal; b) quantitating a mitotic index for the melanoma sample by examining tissue sections of the melanoma
sample using a microscope having high power field capability; c) comparing the mitotic index determined in step b) with a
mitotic index median value determined for a plurality of Stage IIIB and Stage IIIC melanoma samples; d) stratifying the mammal
into a first sub-category of mammals having melanoma samples with a low mitotic index or a second sub-category of mammals
having melanoma samples with a high mitotic index; and e) treating the mammal with a first therapeutic regimen that promotes
immune response in the mammal if the mammal is stratified in the first sub-category of mammals and/or treating the mammal
with a second therapeutic regimen that inhibits cell proliferation in the mammal if the mammal is stratified in the second
sub-category of mammals.
US Pat. No. 9,386,793

COMPOSITIONS AND METHODS FOR TREATING OBESITY AND RELATED DISORDERS BY CHARACTERIZING AND RESTORING MAMMALIAN BACTERIAL MICROBIOTA

New York University, New...

1. A method for preventing weight gain in a mammal in need thereof comprising administering to the mammal a therapeutically
effective amount of a probiotic composition comprising at least one strain from the genus Dorea.
US Pat. No. 9,376,663

GPR15-MEDIATED HOMING AND USES THEREOF

New York University, New...

1. A method for generating a population of CD4+CD3+CD25+T cells that migrates preferentially to the large intestine, the method
comprising the steps of: isolating a population of CD4+CD3+CD25+ T cells from a mammal; and incubating the population of CD4+CD3+CD25+
T cells in culture medium comprising TGF-? and IL-21 to produce a population of CD4+CD3+CD25+T cells having enhanced GPR15
expression, wherein the enhanced GPR15 expression confers on the population of CD4+CD3+CD25+T cells an ability to migrate
preferentially to the large intestine.
US Pat. No. 9,370,531

METHOD OF PROVIDING PATIENT SPECIFIC IMMUNE RESPONSE IN AMYLOIDOSES AND PROTEIN AGGREGATION DISORDERS

New York University, New...

1. A method of treating Alzheimer's Disease pathology, which method comprises:
selecting a subject who has Alzheimer's Disease pathology; and
administering twice per week, to the selected subject an oligonucleotide or modified oligonucleotide containing at least one
unmethylated B-class CpG dinucleotide motif at a dosage in a range of 0.2 mg to 20 mg per kilogram body weight of the selected
subject, wherein said administering is effective to stimulate production of endogenously primed autoantibodies without co-administration
of exogenous immunogens, said autoantibodies having binding specificity for one or more pathological neo-epitopes of amyloid
beta or a beta-amyloid-associated protein, without stimulating production of autoantibodies having binding specificity for
non-pathological epitopes of amyloid beta or a beta-amyloid-associated protein in the subject, thereby treating Alzheimer's
Disease pathology.

US Pat. No. 9,267,171

DNA PHOTOLITHOGRAPHY WITH CINNAMATE CROSSLINKERS

New York University, New...

1. A composition comprising:
a first substrate having a first surface nucleic acid strand comprising a first cinnamate functional group and forming a first
sticky end,

a second substrate having a second surface nucleic acid strand comprising a second cinnamate functional group and forming
a second sticky end, the first sticky end and the second sticky end substantially complementary and hybridizable with each
other;

wherein the first substrate and the second substrate are covalently bonded via the first cinnamate functional group and the
second cinnamate functional group.

US Pat. No. 9,246,929

PROVIDING A FAST, REMOTE SECURITY SERVICE USING HASHLISTS OF APPROVED WEB OBJECTS

Polytechnic Institute of ...

1. A method for reducing user-experienced latencies and server costs encountered when all requested Web objects by a client
device must otherwise pass through a security server system, the method comprising:
a) generating, by the security server system, a list of at least one {validated Web object identifier, validated Web object
hash value} pair;

b) forwarding at least a part of the list to the client device;
c) receiving, by the client device, the at least part of the list;
d) storing, by the client device, the at least part of the list received in a client list of at least one {validated Web object
identifier, validated Web object hash value} pair; and

e) responsive to a request for a Web object by an application at the client device,
1) determining, by the client device, whether or not the requested Web object is included in the client list, and
2) responsive to a determination, by the client device, that the requested Web object is included in the clientlist,
A) fetching, by the client device, the requested Web object from an origin server,
B) receiving, by the client device, the Web object,
C) computing, by the client device, a hash of the received Web object,
D) comparing, by the client device, the computed hash with the hash paired with the requested Web object included in the client
list, and

E) responsive to a determination, by the client device, that the computed hash matches the hash paired with the requested
Web object included in the client list,

i) passing, by the client device, the requested Web object to the application, otherwise, responsive to a determination, by
the client device, that the computed hash does not match the hash paired with the requested Web object included in the client
list, and

ii) requesting, by the client device, the requested Web object via the security server system.

US Pat. No. 9,110,771

COMPUTATIONS USING A POLYCHRONOUS WAVE PROPAGATION SYSTEM

New York University, New...

1. A reverberating memory device comprising:
a plurality of transponders, wherein each of the plurality of transponders is configured to detect simultaneous reception
of memory pulses in a ferromagnetic material having an array of spin-torque nano-oscillators and transmit a memory pulse in
the ferromagnetic material having an array of spin-torque nano-oscillators upon detecting each simultaneous reception of memory
pulses wherein a first logic state corresponds to a state in which the simultaneous reception of memory pulses are regularly
detected, and a second logic state corresponds to a state in which the simultaneous reception of memory pulses are not regularly
detected; and

control circuitry configured to:
receive an indication from at least one of the plurality of transponders that is representative of one of the first logic
state and the second logic state; and

provide an output based on the indication.
US Pat. No. 10,093,970

METHOD FOR SINGLE CELL ANALYSIS OF TELOMERE LENGTH USING PRE-AMPLIFICATION AND MULTIPLE-COPY REFERENCE SEQUENCE

New York University, New...

1. A method for determining relative telomere length in a biological sample, which sample comprises less than 20 ng of genomic DNA, said method comprising:(a) performing a multiplex pre-amplification of DNA contained in the sample for 12-20 cycles using, in a single reaction mixture, a first primer pair specific for a telomere sequence and a second primer pair specific for a reference sequence, wherein the reference sequence is present in multiple copies in the genome,
(b) performing a qPCR reaction on the products of step (a) using the first and the second primer pairs, wherein such primer pairs are the same as in step (a) and are present in a single or separate qPCR reaction mixtures,
(c) calculating a T/R ratio as the ratio of (i) the amount of qPCR product obtained in step (b) using the first primer pair specific for the telomere sequence (T) and (ii) the amount of qPCR product obtained in step (b) using the second primer pair specific for the reference sequence (R), and
(d) determining the relative telomere length for the sample based on the T/R ratio calculated in step (c), wherein the T/R ratio of more than a standard T/R ratio indicates the relative telomere length greater than normal and the T/R ratio of less than the standard T/R ratio indicates the relative telomere length shorter than normal, wherein the standard T/R ratio is (i) a predetermined value, or (ii) an average T/R ratio for multiple corresponding normal cells, tissues or individuals of the same species, or (iii) a standard curve of T/R ratios for multiple corresponding normal cells, tissues or individuals of the same species.

US Pat. No. 9,695,153

OLIGOOXOPIPERAZINES FOR P53 REACTIVATION

New York University, New...

1. A method of treating in a subject a disorder mediated by interaction of E6 with CREB-binding protein and/or p300, said
method comprising:
administering to the subject an oligooxopiperazine that substantially mimics helix ?B of the C-terminal transactivation domain
of Hypoxia-Inducible Factor 1? under conditions effective to treat the disorder, wherein the oligooxopiperazine is Formula
I:

wherein:each of R1, R2, R3, and R4 is independently an amino acid side chain, H, N(R)2, OR, halogen, an alkyl, or an aryl; wherein each R is independently H, an alkyl, or an aryl;each R6 is independently H, N(R)2, OR, halogen, an alkyl, or an aryl; wherein each R is independently H, an alkyl, or an aryl;A is X1 or C, wherein:
X1 is H, COR?, CO2R?, an alkyl, an aryl, an arylalkyl, a cycloalkyl, a heteroaryl, a protecting group for protection of an amine, a targeting
moiety, or a tag; wherein R? is H, an alkyl, an aryl, an arylalkyl, a cycloalkyl, a heteroaryl, a targeting moiety, or a tag;
and

C is a moiety of the formula

wherein:
each X? is independently H, COR?, CO2R?, N(R?)2, an alkyl, an aryl, an arylalkyl, a cycloalkyl, a heteroaryl, a targeting moiety, or a tag; wherein:

R? is H, an alkyl, an aryl, an arylalkyl, a cycloalkyl, a heteroaryl, a targeting moiety, or a tag; and
each R? is independently H, CO2R?, an alkyl, an aryl, an arylalkyl, a cycloalkyl, a heteroaryl, a targeting moiety, or a tag;

R0 is an amino acid side chain, H, N(R)2, OR, halogen, an alkyl, or an aryl; wherein each R is independently H, an alkyl, or an aryl; and

R6 is H, N(R)2, OR, halogen, an alkyl, or an aryl; wherein each R is independently H, an alkyl, or an aryl; and
B is Y or D, wherein:
Y is OR?, COR?, N(R??)2, an alkyl, an aryl, an arylalkyl, a cycloalkyl, a heteroaryl, a protecting group for protection of a carboxylic acid, a targeting
moiety, or a tag;

wherein:
R? is H, an alkyl, an aryl, an arylalkyl, a cycloalkyl, a heteroaryl, a targeting moiety, or a tag; and
each R?? is independently H, CO2R?, an alkyl, an aryl, an arylalkyl, a cycloalkyl, a heteroaryl, a targeting moiety, or a tag; and

D is a moiety of the formula

wherein:
R5 is an amino acid side chain, H, N(R)2, OR, halogen, an alkyl, or an aryl; wherein each R is independently H, an alkyl, or an aryl;

R6 is H, N(R)2, OR, halogen, an alkyl, or an aryl; wherein each R is independently H, an alkyl, or an aryl; and

E is X2 or F, wherein:

X2 is H, COR?, CO2R?, an alkyl, an aryl, an arylalkyl, a cycloalkyl, a heteroaryl, a protecting group for protection of an amine, a targeting
moiety, or a tag; wherein R? is H, an alkyl, an aryl, an arylalkyl, a cycloalkyl, a heteroaryl, a targeting moiety, or a tag;
and

F is a moiety of the formula

wherein:
R6 is H, N(R)2, OR, halogen, an alkyl, or an aryl; wherein each R is independently H, an alkyl, or an aryl;

R7 is an amino acid side chain; and

Y is OR?, COR?, N(R??)2, an alkyl, an aryl, an arylalkyl, a cycloalkyl, a heteroaryl, a protecting group for protection of a carboxylic acid, a targeting
moiety, or a tag; wherein:

 R? is H, an alkyl, an aryl, an arylalkyl, a cycloalkyl, a heteroaryl, a targeting moiety, or a tag; and
 each R?? is independently H, CO2R?, an alkyl, an aryl, an arylalkyl, a cycloalkyl, a heteroaryl, a targeting moiety, or a tag.

US Pat. No. 9,599,671

ARCHITECTURE, SYSTEM, METHOD, AND COMPUTER-ACCESSIBLE MEDIUM FOR PARTIAL-SCAN TESTING

New York University, New...

1. A method for performing a partial-scan test of at least one integrated circuit, comprising:
obtaining a plurality of test cubes including at least one justification cube of the at least one integrated circuit;
identifying a plurality of scan flip-flops in the test cubes; and
with a cube merging procedure, (i) identifying each previously-identified scan flip-flop of the integrated circuit that is
individually convertible to a non-scan flip-flop, and (ii) performing the partial-scan test based on only the test cubes;

wherein the identification procedure of each previously-identified scan flip-flop further includes identifying a particular
previously-identified scan flip-flop (i) where there are no 0-1 conflicts between a particular test cube that requires the
particular previously-identified scan flip-flop to be at a particular value and a particular justification cube associated
with the particular previously-identified scan flip-flop for the particular value, and (ii) where the particular justification
cube does not specify a bit of the particular previously-identified scan flip-flop to a 0 or a 1.

US Pat. No. 9,588,203

APPARATUS, METHOD AND COMPUTER-ACCESSIBLE MEDIUM FOR DETERMINATION OF ELECTRICAL PROPERTIES OF TISSUES AND MATERIALS USING MULTIPLE RADIO FREQUENCY MEASUREMENTS

New York University, New...

1. An assembly that determines at least one of a conductivity or a permittivity of an object, comprising:
at least one transmitter configured to generate a plurality of electromagnetic field distribution patterns directed at an
object; and

a data apparatus, including:
a magnetic resonance (MR) imaging apparatus configured to produce at least two MR images of the object using at least one
of a magnitude or a phase modulated by the electromagnetic field distribution patterns; and

a hardware processing arrangement configured to determine the at least one of the conductivity or the permittivity of the
object from the at least two produced MR images of the object.

US Pat. No. 9,507,734

CORRUPTING DATA STRUCTURES FOR PRIVACY PROTECTION

New York University, New...

1. A system for protecting data comprising:
a unit containing a connection port for a pluggable device and containing both defaultable and non-defaultable memory,
the non-defaultable memory having only corrupted blocks stored therein;
the defaultable memory having seeds and their associated block identifiers stored therein
a pluggable device,
a source of data which may be different from the pluggable device,
wherein defaultable memory is reset to default values when the pluggable device is removed and wherein non-defaultable memory
may not reset to default values when the pluggable device is removed.

US Pat. No. 9,449,668

CURRENT INDUCED SPIN-MOMENTUM TRANSFER STACK WITH DUAL INSULATING LAYERS

New York University, New...

1. A magnetic device comprising:
a pinned magnetic layer with a first magnetization vector with a first magnetization direction that is fixed;
a free magnetic layer with a second magnetization vector with a changeable second magnetization direction;
a first non-magnetic insulating layer that spatially separates the free magnetic layer and the pinned magnetic layer, wherein
the first non-magnetic insulating layer is sufficiently thin such that electrons traverse the first non-magnetic layer by
quantum mechanical tunneling;

a read-out magnetic layer with a third magnetization vector with a third magnetization direction that is fixed, wherein the
first magnetization vector is orthogonal to the second magnetization vector and the third magnetization vector; and

a second non-magnetic insulating layer that spatially separates the free magnetic layer and the read-out magnetic layer, wherein
the second non-magnetic insulating layer is sufficiently thin such that electrons traverse the second non-magnetic layer by
quantum mechanical tunneling.

US Pat. No. 9,254,310

THERAPEUTIC AND COSMETIC USES AND APPLICATIONS OF CALRETICULIN

NEW YORK UNIVERSITY, New...

1. A method of treating wrinkles and/or fine lines in a subject in need thereof, which method comprises administering intradermally
to said wrinkles and/or fine lines an amount of calreticulin, which amount is sufficient to increase the production of collagen
and/or fibronectin and/or elastin by dermal fibroblasts of the subject.

US Pat. No. 9,161,738

ULTRASONIC PROBE DEVICE AND SYSTEM AND METHODS OF GENERATING ULTRASONIC IMAGES

New York University, New...

1. A two-in-one ultrasonic probe device comprising:
an elongated body comprising a shaft portion and a handle portion, the shaft portion and handle portion being joined together
to form the elongated body, the elongated body having a proximal end and a distal end, wherein the distal end comprises a
first coupling and the body comprises a channel that extends from the proximal end to the distal end;

a power cord passing through the channel, wherein the power cord is extendable and retractable relative to the distal end
and proximal end of the elongated body; and

an ultrasonic probe head connected to the power cord, wherein the power cord is capable of delivering power to the probe head,
the probe head comprising a proximal end adjacent the distal end of the elongated body, wherein the proximal end of the probe
head comprises a second coupling that mates with the first coupling to prevent the elongated body from rotating relative to
the ultrasonic probe head, and wherein the second coupling is detachable from the first coupling, wherein when the first coupling
and the second coupling are mated the elongated body and the ultrasonic probe head constitute a transvaginal probe device,
and when the first coupling and the second coupling are detached, the ultrasonic probe head, independent of the elongated
body, constitutes a surface scanning ultrasonic probe device suitable for pediatric applications.

US Pat. No. 9,108,009

SYSTEM AND METHOD FOR DIAGNOSIS AND TREATMENT OF A BREATHING PATTERN OF A PATIENT

NEW YORK UNIVERSITY, New...

1. A positive airway pressure system for delivery of a flow of breathable gas at a positive treatment pressure with respect
to ambient air pressure delivered to an entrance of a patient's airways in order to assist in treating a sleeping disorder
in a patient, the positive airway pressure system comprising:
a flow generator which supplies a positive treatment pressure flow of breathable gases to be supplied to a patient;
a flow sensor located in a flow path of the positive treatment pressure flow of breathable gases, the flow sensor measuring
data corresponding to the flow of breathable gases directed to the patient and indicative of the patient's breathing patterns;
and

a processing arrangement which receives the measured data corresponding to the flow of breathable gases from the flow sensor
and analyzes the data to determine the patient's breathing patterns, the processing arrangement also determines whether to
alter the pressure supplied by the flow generator to the airway of the patient based, at least in part, on the determined
breathing patterns of the patient, wherein the processing arrangement automatically delays the onset of a pressure increase
to the patient when the processing arrangement determines that the patient is in an awake state, wherein the delay lasts at
least until the processing arrangement determines that the patient is in an asleep state, wherein the processing arrangement
determines the patient has transitioned between an awake state and an asleep state when a combination of obstructions are
detected.

US Pat. No. 9,661,051

STREAMLOADING CONTENT, SUCH AS VIDEO CONTENT FOR EXAMPLE, BY BOTH DOWNLOADING ENHANCEMENT LAYERS OF THE CONTENT AND STREAMING A BASE LAYER OF THE CONTENT

New York University, New...

1. A computer-implemented method for playing media content which is divided into a sequence of temporal chunks, each chunk
including a base layer subchunk and at least two enhancement layer subchunks, the computer-implemented method comprising:
a) requesting, by a client device, (1) at least one enhancement layer subchunk of at least one chunk of the media content
and (2) at least one base layer subchunk of the media content;

b) receiving, by the client device the at least one enhancement subchunk of the at least one chunk of the media content and
the at least one base layer subchunk of the media content;

c) decoding, by the client device, the media content using both (1) at least one enhancement layer subchunk of the at least
one chunk of the media content and (2) the at least one base layer subchunk of the media content; and

d) playing, by the client device, the decoded media content,
wherein the act of requesting at least one enhancement layer subchunk of at least one chunk of the media content is performed
in accordance with a sliding quality window, and

wherein while a pth chunk cp is playing, the computer-implemented method (1) first requests all base layer subchunks after the pth chunk but before the (p+b)th chunk, where b is defined as a buffer size, with earlier chunks being requested first, and (2) then requests enhancement layer
subchunks after the pth chunk, falling within the sliding quality window, layer by layer, where earlier subchunks within a layer are requested before
later subchunks within the layer, whereby a size of the sliding quality window affects whether (A) a conservative, time first,
request strategy, which favors uninterrupted play over quality, (B) an aggressive, quality first, request strategy, which
favors quality over uninterrupted play, or (C) a diagonal strategy, is used.

US Pat. No. 9,682,947

SUBSTITUTED LACTONES FOR TREATING CANCER

New York University, New...

34. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

US Pat. No. 9,605,026

HYDROGEN-BOND SURROGATE PEPTIDES AND PEPTIDOMIMETICS FOR P53 REACTIVATION

NEW YORK UNIVERSITY, New...

1. A peptidomimetic, wherein the peptidomimetic is selected from the group consisting of:
(i) a compound of Formula Ia, Ib, Ic, Id, Ie, or If:

wherein:
B is C(R1)(R1?), O, S, or NR1;

is a double bond and each R1? is absent; or is a single bond and each R1? is independently hydrogen, an amino acid side chain, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a heterocyclyl, an aryl,
a heteroaryl, or an arylalkyl;

each R1 is independently hydrogen, an amino acid side chain, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a heterocyclyl, an aryl,
a heteroaryl, or an arylalkyl; and

wherein:
(a) at least one R1 at the positions labeled “Glu” is a glutamic acid side chain,

(b) at least one R1 at the positions labeled “Leu” is a leucine side chain,

(c) at least one R1 at the positions labeled “Ala” is an alanine side chain,

(d) at least one R1 at the positions labeled “Arg” is an arginine side chain,

(e) at least one R1 at the positions labeled “Asp” is an aspartic acid side chain, and

(f) at least one R1 at the positions labeled “Gln” is a glutamine side chain;

R2 is hydrogen; an alkyl; an alkenyl; an alkynyl; a cycloalkyl; a heterocyclyl; an aryl; a heteroaryl; an arylalkyl; an alpha
amino acid; a beta amino acid; a peptide; a targeting moiety; a tag; —OR5 wherein R5 is hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a heterocyclyl, an aryl, a heteroaryl, an arylalkyl, an acyl,
a peptide, a targeting moiety, or a tag; —(CH2)0-1N(R5)2 wherein each R5 is independently hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a heterocyclyl, an aryl, a heteroaryl, an arylalkyl,
an acyl, a peptide, a targeting moiety, or a tag; or a moiety of Formula A:


R2? is hydrogen; an alkyl; an alkenyl; an alkynyl; a cycloalkyl; a heterocyclyl; an aryl; a heteroaryl; an arylalkyl; an alpha
amino acid; a beta amino acid; a peptide; a targeting moiety; a tag; —OR5 wherein R5 is hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a heterocyclyl, an aryl, a heteroaryl, an arylalkyl, an acyl,
a peptide, a targeting moiety, or a tag; or —(CH2)0-1N(R5)2 wherein each R5 is independently hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a heterocyclyl, an aryl, a heteroaryl, an arylalkyl,
an acyl, a peptide, a targeting moiety, or a tag;

R3 is hydrogen; an alkyl; an alkenyl; an alkynyl; a cycloalkyl; a heterocyclyl; an aryl; a heteroaryl; an arylalkyl; an alpha
amino acid; a beta amino acid; a peptide; a targeting moiety; a tag; —OR5 wherein R5 is hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a heterocyclyl, an aryl, a heteroaryl, an arylalkyl, an acyl,
a peptide, a targeting moiety, or a tag; —N(R5)2 wherein each R5 is independently hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a heterocyclyl, an aryl, a heteroaryl, an arylalkyl,
an acyl, a peptide, a targeting moiety, or a tag; or a moiety of Formula B:


R3? is hydrogen; an alkyl; an alkenyl; an alkynyl; a cycloalkyl; a heterocyclyl; an aryl; a heteroaryl; an arylalkyl; an alpha
amino acid; a beta amino acid; a peptide; a targeting moiety; a tag; —OR5 wherein R5 is hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a heterocyclyl, an aryl, a heteroaryl, an arylalkyl, an acyl,
a peptide, a targeting moiety, or a tag; or —N(R5)2 wherein each R5 is independently hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a heterocyclyl, an aryl, a heteroaryl, an arylalkyl,
an acyl, a peptide, a targeting moiety, or a tag;

each R4 is independently hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a heterocyclyl, an aryl, a heteroaryl, or an arylalkyl;

R4? is hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a heterocyclyl, an aryl, a heteroaryl, an arylalkyl, or a double
bond between C(R4?,R4) and B;

a is one or two;
each b is independently one or two;
c is one or two;
each d is independently one or two;
m? is zero or any number;
m? is zero or any number;
n? and n? are each independently zero, one, two, three, or four;
each o is independently one or two; and
p is one or two;
(ii) a compound of Formula IIa, IIb, IIc, IId, or, IIe:

wherein:
each R1 is independently hydrogen, an amino acid side chain, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a heterocyclyl, an aryl,
a heteroaryl, or an arylalkyl; and

wherein:
(a) at least one R1 at the positions labeled “Glu” is a glutamic acid side chain,

(b) at least one R1 at the positions labeled “Leu” is a leucine side chain,

(c) at least one R1 at the positions labeled “Ala” is an alanine side chain,

(d) at least one R1 at the positions labeled “Arg” is an arginine side chain,

(e) at least one R1 at the positions labeled “Asp” is an aspartic acid side chain, and

(f) at least one R1 at the positions labeled “Gln” is a glutamine side chain;

R2 is hydrogen; an alkyl; an alkenyl; an alkynyl; a cycloalkyl; a heterocyclyl; an aryl; a heteroaryl; an arylalkyl; an alpha
amino acid; a beta amino acid; a peptide; a targeting moiety; a tag; —OR5 wherein R5 is hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a heterocyclyl, an aryl, a heteroaryl, an arylalkyl, an acyl,
a peptide, a targeting moiety, or a tag; —(CH2)0-1N(R5)2 wherein each R5 is independently hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a heterocyclyl, an aryl, a heteroaryl, an arylalkyl,
an acyl, a peptide, a targeting moiety, or a tag; or a moiety of Formula A:


R2? is hydrogen; an alkyl; an alkenyl; an alkynyl; a cycloalkyl; a heterocyclyl; an aryl; a heteroaryl; an arylalkyl; an alpha
amino acid; a beta amino acid; a peptide; a targeting moiety; a tag; —OR5 wherein R5 is hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a heterocyclyl, an aryl, a heteroaryl, an arylalkyl, an acyl,
a peptide, a targeting moiety, or a tag; or —(CH2)0-1N(R5)2 wherein each R5 is independently hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a heterocyclyl, an aryl, a heteroaryl, an arylalkyl,
an acyl, a peptide, a targeting moiety, or a tag;

R3 is hydrogen; an alkyl; an alkenyl; an alkynyl; a cycloalkyl; a heterocyclyl; an aryl; a heteroaryl; an arylalkyl; an alpha
amino acid; a beta amino acid; a peptide; a targeting moiety; a tag; —OR5 wherein R5 is hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a heterocyclyl, an aryl, a heteroaryl, an arylalkyl, an acyl,
a peptide, a targeting moiety, or a tag; —N(R5)2 wherein each R5 is independently hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a heterocyclyl, an aryl, a heteroaryl, an arylalkyl,
an acyl, a peptide, a targeting moiety, or a tag; or a moiety of Formula B:


R3? is hydrogen; an alkyl; an alkenyl; an alkynyl; a cycloalkyl; a heterocyclyl; an aryl; a heteroaryl; an arylalkyl; an alpha
amino acid; a beta amino acid; a peptide; a targeting moiety; a tag; —OR5 wherein R5 is hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a heterocyclyl, an aryl, a heteroaryl, an arylalkyl, an acyl,
a peptide, a targeting moiety, or a tag; or —N(R5)2 wherein each R5 is independently hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a heterocyclyl, an aryl, a heteroaryl, an arylalkyl,
an acyl, a peptide, a targeting moiety, or a tag;

each b is independently one or two;
c is one or two;
each d is independently one or two;
m? is zero or any number;
m? is zero or any number;
each o is independently one or two;
one of p? and p? is zero and the other is zero or one;
one of q? and q? is zero and the other is zero or one;
s is one, two, three, four, or five; and
Y—X is a hydrocarbon, an amide bond, an alkane, an alkene, an alkyne, a triazole, or a disulfide bond; and
(iii) a compound of Formula IIIa:

wherein:
B is C(R1)(R1?), O, S, or NR1;

is a double bond and each R1? is absent; or is a single bond and each R1? is independently hydrogen, an amino acid side chain, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a heterocyclyl, an aryl,
a heteroaryl, or an arylalkyl;

each R1 is independently hydrogen, an amino acid side chain, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a heterocyclyl, an aryl,
a heteroaryl, or an arylalkyl; and

wherein:
(a) at least one R1 at the positions labeled “Glu” is a glutamic acid side chain,

(b) at least one R1 at the positions labeled “Leu” is a leucine side chain,

(c) at least one R1 at the positions labeled “Ala” is an alanine side chain,

(d) at least one R1 at the positions labeled “Arg” is an arginine side chain,

(e) at least one R1 at the positions labeled “Asp” is an aspartic acid side chain, and

(f) at least one R1 at the positions labeled “Gln” is a glutamine side chain;

R2 is hydrogen; an alkyl; an alkenyl; an alkynyl; a cycloalkyl; a heterocyclyl; an aryl; a heteroaryl; an arylalkyl; an alpha
amino acid; a beta amino acid; a peptide; a targeting moiety; a tag; —OR5 wherein R5 is hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a heterocyclyl, an aryl, a heteroaryl, an arylalkyl, an acyl,
a peptide, a targeting moiety, or a tag; —(CH2)0-1N(R5)2 wherein each R5 is independently hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a heterocyclyl, an aryl, a heteroaryl, an arylalkyl,
an acyl, a peptide, a targeting moiety, or a tag; or a moiety of Formula A:


wherein:
R2? is hydrogen; an alkyl; an alkenyl; an alkynyl; a cycloalkyl; a heterocyclyl; an aryl; a heteroaryl; an arylalkyl; an alpha
amino acid; a beta amino acid; a peptide; a targeting moiety; a tag; —OR5 wherein R5 is hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a heterocyclyl, an aryl, a heteroaryl, an arylalkyl, an acyl,
a peptide, a targeting moiety, or a tag; or —(CH2)0-1N(R5)2 wherein each R5 is independently hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a heterocyclyl, an aryl, a heteroaryl, an arylalkyl,
an acyl, a peptide, a targeting moiety, or a tag;

m? is zero or any number;
each b is independently one or two; and
c is one or two;
R3 is hydrogen; an alkyl; an alkenyl; an alkynyl; a cycloalkyl; a heterocyclyl; an aryl; a heteroaryl; an arylalkyl; an alpha
amino acid; a beta amino acid; a peptide; a targeting moiety; a tag; —OR5 wherein R5 is hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a heterocyclyl, an aryl, a heteroaryl, an arylalkyl, an acyl,
a peptide, a targeting moiety, or a tag; —N(R5)2 wherein each R5 is independently hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a heterocyclyl, an aryl, a heteroaryl, an arylalkyl,
an acyl, a peptide, a targeting moiety, or a tag; or a moiety of Formula B:


wherein:
R3? is hydrogen; an alkyl; an alkenyl; an alkynyl; a cycloalkyl; a heterocyclyl; an aryl; a heteroaryl; an arylalkyl; an alpha
amino acid; a beta amino acid; a peptide; a targeting moiety; a tag; —OR5 wherein R5 is hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a heterocyclyl, an aryl, a heteroaryl, an arylalkyl, an acyl,
a peptide, a targeting moiety, or a tag; or —N(R5)2 wherein each R5 is independently hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a heterocyclyl, an aryl, a heteroaryl, an arylalkyl,
an acyl, a peptide, a targeting moiety, or a tag;

m? is zero or any number; and
each d is independently one or two;
each R4 is independently hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a heterocyclyl, an aryl, a heteroaryl, or an arylalkyl;

R4? is hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a heterocyclyl, an aryl, a heteroaryl, an arylalkyl, or a double
bond between C(R4?,R4) and B;

n? and n? are each independently zero, one, two, three, or four;
each o is independently one or two;
p is one or two;
one of p? and p? is zero and the other is zero or one;
one of q? and q? is zero and the other is zero or one;
s is one, two, three, four, or five; and
Y—X is a hydrocarbon, an amide bond, an alkane, an alkene, an alkyne, a triazole, or a disulfide bond.

US Pat. No. 9,588,202

LONGEVITY OF HYPERPOLARIZED ENHANCED SIGNALS FOR 1H NMR SPECTROSCOPY

New York University, New...

1. A system comprising:
a source of hyperpolarization material;
a reaction vessel for converting the hyperpolarization material from an ortho spin state to a para spin state; and
an injection system for dispersing the hyperpolarization material into a sample container having a surfactant and a hyperpolarizable
NMR material;

wherein the para-hyperpolarization material hyperpolarizes the NMR material.

US Pat. No. 9,489,636

TASK-AGNOSTIC INTEGRATION OF HUMAN AND MACHINE INTELLIGENCE

Tagasauris, Inc., New Yo...

1. A computer-implemented method comprising:
receiving at least one user action from a user input device, the at least one user action including a plurality of actions
performed on an object;

determining a type of object that includes the object on which the at least one user action was performed;
determining a feature vector of the at least one user action and the object type on which the at least one user action was
performed;

using the at least one user action and the feature vector to create a set of training data, the training data used to predict
future user actions for objects of the type and to determine an accuracy of the predicted future user actions; and

selecting a sample size of users from which to receive additional user actions for the object, the sample size selected responsive
to the determined accuracy of the predicted future user actions, the sample size reflecting an extent to which the predicted
future user actions substitute for the at least one user action from the user input device, substitution beginning at least
in response to the determined accuracy of the predicted user actions being at or near the accuracy of the at least one user
action and the extent of substitution increasing over time as the determined accuracy of predicted user actions improves relative
to the accuracy of the at least one user action.

US Pat. No. 9,273,015

S-TRIAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME

NEW YORK UNIVERSITY, New...

1. A method for treating a bacterial infection which comprises administering to a patient in need of such treatment, a therapeutically
effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective
amount of an s-triazine compound having a formula:

wherein
each L1 and L2 is independently selected from a single bond, or C1-C4 alkylene;

L3 is selected from C2-C6 alkylene, C2-C6 alkenyl, and C2-C6 alkynyl;

each R1 and R2 is independently selected from hydrogen, and substituted or unsubstituted C1-C6 alkyl; or

R1 and R2 may join together to form a 4-7 membered heterocycloalkyl; or

R1 is H; and R2 is —C(?NH)—NH2;

R3 is R4; or R3 is selected from substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl;

R4 is substituted or unsubstituted


each X is C or N; provided that no more than three Xs are N at one time;
each Y is C or N; provided that no more than three Ys are N at one time;
R6 is H or substituted or unsubstituted C1-C6 alkyl;

each R5a, R5b, or R5c is independently H or substituted or unsubstituted C1-C6 alkyl;

or a pharmaceutically acceptable salt thereof;
and stereoisomers or tautomers thereof;
wherein the bacterial infection is due to A. Baumannii, E. Coli or Staphylococcus Aureus (MSRA).

US Pat. No. 9,262,292

TEST ACCESS SYSTEM, METHOD AND COMPUTER-ACCESSIBLE MEDIUM FOR CHIPS WITH SPARE IDENTICAL CORES

New York University, New...

21. A system for testing a multi-core chip having a plurality of identical cores, comprising:
a computer arrangement which is configured to compare each of the cores from the multi-core chip to one another using a first
number of on-chip comparators which corresponds to a second number of spare cores plus 1.

US Pat. No. 9,199,005

CALCIUM PHOSPHATE-BASED MATERIALS CONTAINING ZINC, MAGNESIUM, FLUORIDE AND CARBONATE

New York University, New...

1. A biomaterial comprising a carbonate-containing calcium phosphate matrix comprising two or more phases, said matrix incorporating
concentrations of magnesium, zinc, and fluorine ions.

US Pat. No. 9,171,271

COMPUTER SYSTEM, CLIENT DEVICE AND METHOD

New York University, New...

1. A computer system comprising:
a network;
a first client device in communication with the network having a first transaction description for a transaction t and sending
said first transaction description to a second client device in communication with the network, the second client device receives
the first transaction description from the first client device, one of said first or second client devices executes the first
transaction description and creates a second transaction description for transaction t which tells which records to modify
or insert and how for transaction t and then sends the second transaction description to a client device, the first and second
client devices each having a database;

a storage device having a database wherein said storage device is in communication with the first and second client devices
through the network, the first and second client devices each having a copy of a portion of the database of the storage device
where the portion of the storage device's database of the first device is allowed to be different from the portion of the
storage device's database of the second device, each client device has at least a portion of a copy of data in the database
and performs at least a portion of reads of transactions at each of said client devices on the portion of the copy of the
data in the storage device's database that each client device also has; the copy of the portion of the storage device's database
that each client device has is subject to access privacy because all data accesses that go to each client's database, have
a property that the storage device does not know which data items are in each copy of the portion of the storage device's
database of the first or second client devices nor does the storage device know which data items are accessed nor whether
a same data item is accessed more than once, the storage device receives only encrypted data 1; the storage device is a backup
for data of each client device so if any client device needs to recover data, the data is able to be retrieved from the storage
device; and

a conduit which orders transactions in communication with the storage device and each client device through the network, wherein
all read-write transactions pass through the conduit so that read-write transactions are executed in a same order in every
client.

US Pat. No. 9,809,811

METHOD OF RANDOM CIRCULAR PERMUTATION BY MUCP-ISC AND MUCP-ISSC TRANSPOSONS

New York University, New...

16. A method for designing circular permuted proteins, comprising:
a) constructing random circular permuted proteins using a Mu Circular permutation transposon (MuCP);
b) restricting the length of the appended amino acids to 1 at N-terminus for the MuCP and to 2 or 3 at C-terminus for the
MuCP;

c) comprising giving flexibility to the length of the linker sequence connecting the N and C termini for the MuCP.
US Pat. No. 9,623,059

ONCOLYTIC HERPES SIMPLEX VIRUS AND THERAPEUTIC USES THEREOF

New York University, New...

1. A variant oncolytic herpes simplex virus (HSV) comprising:
(a) functionally inactive ICP34.5 encoding genes;
(b) a US11 encoding gene operably associated with an immediate early (IE) promoter; and
(c) a virus-derived heterologous transporter associated with antigen presentation (TAP) inhibitor.

US Pat. No. 9,423,476

APPARATUS, SYSTEMS AND METHODS FOR FACILITATING SIGNAL EXCITATION AND/OR RECEPTION IN A MAGNETIC RESONANCE SYSTEM

New York University, New...

1. A method for facilitating signal excitation and reception in a magnetic resonance system, comprising:
arranging an electrically continuous circular conductive structure lying in a transverse plane within a scanner bore, wherein
the electrically continuous circular structure is concentric with a center of a scanner radio frequency (RF) shield; and

arranging the electrically continuous circular structure so as to have a resonant mode at a magnetic resonance (MR) frequency
characterized by a current pattern, the current pattern being configured for exciting and receiving a waveguide mode,

wherein the electrically continuous circular conductive structure includes two circular elements separated from one another
and lying in the transverse plane which are connected to each other in the transverse plane at a plurality of locations.

US Pat. No. 9,358,281

METHODS, AGENTS AND PEPTIDES FOR INDUCING AN INNATE IMMUNE RESPONSE IN HIV VACCINATION

New York University, New...

1. A method for stimulating or enhancing innate immune response to HIV-1 comprising administering in an immunogenic composition
HIV-1 viral particles comprising a Vpx protein and a replication defective HIV-1 vector encoding an HIV-1 Gag polypeptide
(SEQ ID NO: 4), wherein the Vpx protein is fused to a Vpr protein in a Vpx-Vpr fusion protein comprising SEQ ID NO: 51 and
the Vpr protein of the Vpx-Vpr fusion protein facilitates incorporation of the Vpx-Vpr fusion protein into the HIV-1 viral
particles.
US Pat. No. 9,359,408

FLUORINATED PROTEIN-BASED POLYMERIC CARRIERS

New York University, New...

1. A protein polymer comprising:
a) an elastin-like peptide (ELP) domain; and
b) a coiled-coil domain of cartilage oligomeric matrix protein (COMPcc);
wherein at least one of the ELP and the COMPcc incorporates at least one fluorinated amino acid residue.
US Pat. No. 9,335,325

IMMUNODOMINANT MYCOBACTERIUM TUBERCULOSIS PEPTIDES FROM CELL WALL PROTEINS FOR EARLY DIAGNOSIS AND IMMUNIZATION

NEW YORK UNIVERSITY, New...


wherein said Pt-# peptides are fragments of the Mycobacterium tuberculosis(Mtb) protein PTRP (SEQ ID NO:2), said Pg-# peptides are fragments of the Mtb protein PE-PGRS51 (SEQ ID NO:4), and said Lp-#
peptides are fragments of the Mtb protein LipC (SEQ ID NO:6), or

(ii) a fragment of at least 10 residues of the peptide of (a)(i) or a conservative amino acid substitution variant of the
peptide of (a)(i), which fragment or variant binds to an antibody specific for said PTRP protein, said PE-PGRS51 protein or
said LipC protein of which said peptide of (a)(i) is a fragment,

(b) linked to the peptide of (a)(i), or to the fragment or variant of (a)(ii), a second fusion partner polypeptide that is
an early Mtb antigen,
wherein the fusion polypeptide includes an optional linker or linkers linking any two or more of said fusion partners, said
early Mtb antigen being one that induces an antibody response in an infected subject either before or after onset of constitutional
symptoms of TB, but before the onset of specific symptoms identifiable as advanced TB that is distinguished by (A) smear positivity
of sputum or other pulmonary associated fluid for acid-fast bacilli, (B) cavitary pulmonary lesions, or both (A) and (B).
US Pat. No. 9,101,559

LEUKEMIC CELL CNS INFILTRATION CONTROLLED BY NOTCH-INDUCED CHEMOTAXIS

New York University, New...

1. A method of inhibiting development of central nervous system leukemia in a subject, said method comprising:
selecting a subject having T-cell acute lymphoblastic leukemia, wherein said subject does not have central nervous system
leukemia;

providing a CCR7 antibody; and
administering the CCR7 antibody to the selected subject under conditions effective to inhibit development of central nervous
system leukemia in the selected subject.

US Pat. No. 10,073,728

SYSTEM, METHOD AND COMPUTER-ACCESSIBLE MEDIUM FOR FAULT ANALYSIS DRIVEN SELECTION OF LOGIC GATES TO BE CAMOUFLAGED

New York University, New...

1. A non-transitory computer-accessible medium including instructions thereon for camouflaging at least one logic gate in at least one integrated circuit, wherein, when a computer hardware arrangement executes the instructions, the computer arrangement is configured to perform procedures comprising:determining at least one camouflaging location of the at least one logic gate using (i) a fault analysis procedure to model an incorrect reverse engineering configuration, and (ii) a fault simulation procedure to determine an effect of the incorrect reverse engineering configuration on at least one output of the at least one integrated circuit; and
camouflaging the at least one logic gate at the at least one location based on the determination.
US Pat. No. 9,943,398

INCREASING SURVIVAL OF FREE TISSUE GRAFTS AND FLAPS USING PHOSPHODIESTERASE TYPE 5 (PDE5) INHIBITORS

New York University, New...

1. A method of increasing the survival of an autologous fat tissue graft, said method comprising:administering, subcutaneously, a phosphodiesterase type-5 (PDE5) inhibitor to a site on subject, said site comprising a fat depot suitable for use as an autologous fat tissue graft;
harvesting an autologous fat tissue graft from the site of the subject after said administering; and
implanting the harvested autologous fat tissue graft into the subject, wherein said implanted autologous fat tissue graft survives longer after said implanting than an autologous fat tissue graft harvested from a site that was not administered a PDE5 inhibitor.

US Pat. No. 9,658,100

SYSTEMS AND METHODS FOR AUDIO INFORMATION ENVIRONMENTAL ANALYSIS

NEW YORK UNIVERSITY, New...

1. An environmental analysis system comprising:
an environmental analysis main device including a first central processing unit and a first communication module, the environmental
analysis main device in communication with a server;

a plurality of remote sensing devices each having at least one microphone, a second central processing unit, a second communication
module, and a power source, each second communication module of the plurality of remote sensing devices in communication with
the first communication module of the environmental analysis main device;

one or more loudspeakers each associated with one or more of the plurality of remote sensing devices; and
an external module having a microphone in communication with an opto-isolation transmitter paired with an opto-isolation receiver
in communication with the environmental analysis main device.

US Pat. No. 9,562,892

METHODS AND AGENTS FOR MODULATING PROTOCADHERIN-18 ACTIVITY

New York University, New...

1. A method for screening to identify agents that modulate pcdh18 mediated inhibition of T cell effector function, the method
comprising: a) contacting a T cell expressing pcdh18 with a population of pcdh18 molecules in the presence or absence of a
candidate modulator agent; and b) determining the ability of the candidate modulator agent to modulate proximal T cell receptor
signaling, wherein a change in proximal T cell receptor signaling in the presence of the candidate modulator agent relative
to that in the absence of the candidate modulator agent or in the presence of a control agent identifies the candidate modulator
agent as a modulator pcdh18 mediated inhibition of T cell effector function.
US Pat. No. 9,551,002

PERICYCLE-SPECIFIC EXPRESSION OF MICRORNA167 IN PLANTS

New York University, New...

1. A method of producing a transgenic plant having decreased ARF6-mediated nitrogen-responsiveness, said method comprising
overexpressing miR167 specifically in the pericycle of the plant by transforming the plant with a polynucleotide construct
comprising a sequence encoding miR167 operably linked to a pericycle-specific promoter, wherein the promoter is optionally
linked to an inducible promoter element, wherein the ARF6-mediated nitrogen responsiveness is decreased in the transgenic
plant as compared to a wild type plant.
US Pat. No. 9,539,315

METHODS, AGENTS AND PEPTIDES FOR INHIBITING MATRIX METALLOPROTEINASE-2 SIGNALING

New York University, New...

1. A method for screening to identify a modulator of matrix metalloproteinase protein-2 (MMP-2) mediated activation of toll-like
receptor-2 (TLR-2), the method comprising: contacting a composition comprising TLR-2 and MMP-2 with a candidate modulator
agent, wherein MMP-2 is a protein comprising or consisting of SEQ ID NO: 1 or a protein at least 90% identical to SEQ ID NO:
1, wherein said protein at 90% identical to SEQ ID NO: 1 activates TLR-2, and measuring direct interaction of TLR-2 and MMP-2
to assess TLR-2/MMP-2 interaction levels in the presence of the candidate modulator agent, wherein detecting a change in TLR-2/MMP-2
interaction levels in the presence of the candidate modulator agent relative to TLR-2/MMP-2 interaction levels in the presence
of a control agent identifies a modulator of MMP-2 mediated activation of TLR-2.

US Pat. No. 9,519,129

METHOD AND SYSTEM FOR MEASURING POROSITY OF PARTICLES

New York University, New...

7. A method of analyzing a particle in suspension, comprising the steps of:
providing a video holographic microscope;
providing a laser source for producing a collimated output beam comprised of a plurality of different wavelengths of light;
scattering the collimated output beam off the particle by simultaneously using the plurality of different wavelengths of light
to generate a plurality of scattered beams and a combination of the scattered beams and an unscattered portion of the output
beam to generate a plurality of interference patterns;

recording intensity of the interference pattern;
analyzing the interference patterns through application of a Lorenz-Mie formalism to determine at least one of the refractive
index of the particle and the medium disposed in the porosity of the particle wherein the Lorenz-Mie formalism comprises,

I(r)=|E0(r)+E0(rp)fs(k(r?rp))|2,

where I(r) is intensity of the interference pattern recorded at position r, E0(r) is the electric field of the output laser at position r, rp is the position of the particle, k is the wavenumber of the light, and fs(kr) is the Lorenz-Mie scattering function that describes scattering of light by the particle, wherein the Lorenz-Mie scattering
function depends on radius of the particle, ap, and on effective refractive index np of the particle; and

determining a measure of at least one of porosity of the particle and a medium disposed in the porosity of the particle.
US Pat. No. 9,481,723

METHODS OF TREATING AND PREVENTING STAPHYLOCOCCUS AUREUS INFECTIONS AND ASSOCIATED CONDITIONS

New York University, New...

1. A composition comprising one or more Staphylococcus aureus-specific neutralizing monoclonal Leukocidin D (LukD) antibodies or fragments thereof, wherein said neutralizing monoclonal
LukD antibodies and fragments thereof bind to an epitope of LukD, within a region of LukD selected from amino acid residues
33-51 of SEQ ID NO: 22, amino acid residues 94-113 of SEQ ID NO: 22, amino acid residues 115-131 of SEQ ID NO: 22, amino acid
residues 229-274 of SEQ ID NO: 22, amino acid residues 59-75 of SEQ ID NO: 22, and amino acid residues 170-220 of SEQ ID NO:
22 and a pharmaceutically acceptable carrier component.
US Pat. No. 9,474,785

CHIMERIC FIBROBLAST GROWTH FACTOR 19 PROTEINS AND METHODS OF USE

New York University, New...

1. A chimeric protein comprising:
an N-terminus coupled to a C-terminus,
wherein the N-terminus comprises an FGF2 portion beginning at any one of residues 1 to 25 and ending at any one of residues
151-155 of SEQ ID NO: 121,

wherein the FGF2 amino acid positions corresponding to those selected from the group consisting of N36, K128, R129, K134,
K138, Q143, K144, and combinations thereof are substituted to decrease binding affinity for heparin and/or heparan sulfate
compared to FGF2 without the substitution, and

wherein the C-terminus comprises a portion of an FGF19 comprising amino acid residues 169 to 216 of SEQ ID NO: 233.
US Pat. No. 9,457,016

METHODS FOR TREATING POLYCYSTIC KIDNEY DISEASE

New York University, New...

1. A method for treating autosomal dominant polycystic kidney disease, the method comprising administering to a subject in
need thereof a therapeutically effective amount of an inhibitor of glutaminase 1 activity, wherein the inhibitor of glutaminase
1 activity is bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES) or an analog thereof, or a composition
of BPTES or an analog thereof.

US Pat. No. 9,427,539

SYSTEM AND METHOD FOR DIAGNOSIS AND TREATMENT OF A BREATHING PATTERN OF A PATIENT

NEW YORK UNIVERSITY, New...

1. A positive airway pressure system for treatment of a sleeping disorder in a patient, the system comprising:
a generator supplying airflow to an airway of a patient;
one or more flow sensors measuring data corresponding to the supplied airflow; and
at least one hardware processor,
wherein the hardware processor receives the measured data from the one or more flow sensors and provides operational control
signals to the generator,

wherein the hardware processor analyzes the measured data to determine whether a patient breathing pattern indicative at least
one transition between an awake state and an asleep state has occurred, the hardware processor providing instructions to the
generator to adjust the applied pressure in response to the patient's breathing patterns indicative of the at least one transition.

US Pat. No. 9,403,891

METHODS AND COMPOSITIONS FOR MODULATING TNF/TNFR SIGNALING

New York University, New...

1. An isolated peptide comprising the contiguous sequence of SEQ ID NO:4 and having 90%-99.4% sequence identity to SEQ ID
NO:4.
US Pat. No. 9,395,368

METHODS, AGENTS AND PEPTIDES FOR INDUCING AN IMMUNE RESPONSE TO MATRIX METALLOPROTEINASE-2 EXPRESSING TUMORS

New York University, New...

1. A method for monitoring and assessing immune response to a matrix metalloproteinase-2 (MMP-2) expressing tumor comprising
assessing enhanced cell mediated responses to MMP-2, the method comprising: inducing enhanced cell mediated immune responses
by contacting at least one of CD4+TH1 cells and dendritic cells with at least one MMP-2 peptide, wherein the at least one MMP-2 peptide consists of 20-25 contiguous
amino acids of SEQ ID NO: 1 comprising amino acids 601-620 of SEQ ID NO: 1 (P601-620), amino acids 621-640 of SEQ ID NO: 1
(P621-640), or amino acids 630-650 of SEQ ID NO: 1 (P630-650); or a composition comprising the at least one MMP-2 peptide
and detecting an increase in at least one of MMP-2-specific CD4+TH1 cells and dendritic cells expressing type-I IFN receptor (IFNAR1), wherein the increase is indicative of the immune response
to the MMP-2 expressing tumor.
US Pat. No. 9,381,245

METHODS FOR INHIBITING OSTEOLYSIS

New York University, New...

1. A method for therapeutically inhibiting, reducing or slowing osteolysis comprising administering to a subject a therapeutically
effective amount of an anti-netrin-1 antibody, and one or more other agents effective to inhibit bone resorption or differentiation
or stimulation of osteoclasts.

US Pat. No. 9,348,463

RETROREFLECTION BASED MULTITOUCH SENSOR, METHOD AND PROGRAM

New York University, New...

1. A detection apparatus comprising:
a first light source which produces light;
a multilocation sensor having an aperture; and
a sheet which receives light from the first light source, the sheet in communication with the multilocation sensor, which
when a plurality of locations of the sheet are simultaneously activated by an object touching the sheet, the sensor senses
these locations based on retroreflection of the light, simultaneously, the sheet includes a first lenslet array, a surface
of the sheet is at a focal length of each lenticular lens of the first lenslet array, the first lenslet array is placed so
that the first lenslet array's ridged side is facing toward the multilocation sensor and the first lenslet array's smooth
side is facing away from the multilocation sensor, the smooth side forms the sheet's surface, the first light source is placed
such that a line in space between the first light source and the aperture of the multilocation sensor is parallel to a line
in space formed by each individual lenticular lenslet of the first lenslet array, light that arrives at the sheet from any
direction is focused by each lenticular lens into a thin bright line of light upon the smooth side of the lenticular lens
array so that light is concentrated into thin bright parallel stripes of light upon the smooth side of the sheet, when the
light contacts the object touching the surface, the light is collimated retroreflected directly back toward the source.

US Pat. No. 9,295,948

SYSTEM, METHOD AND COMPUTER-ACCESSIBLE MEDIUM FOR DETERMINING MEMBRANE PROPERTIES RELATING TO DIFFUSION

New York University, New...

1. A non-transitory computer-accessible medium having instructions thereon, wherein, when a computing arrangement executes
the instructions, the computing arrangement is configured to execute procedures comprising:
(a) causing an activation of an apparatus that measures at least one transport property of a material containing at least
one membrane, wherein the apparatus includes one of (i) a magnetic resonance imaging apparatus, (ii) a nuclear magnetic resonance
apparatus or (iii) an electron spin resonance apparatus;

(b) obtaining particular information from the apparatus relating to the at least one transport property of the a material;
and

(c) determining at least one of a (i) a permeability of the at least one membrane, or (ii) a surface area of the at least
one membrane, as a function of the obtained particular information and a diffusivity model given by the following expression:


where (i) Deff(?) is a frequency-dependent complex-valued effective diffusivity, (ii) D is a free diffusivity, (iii) ?=(S/V)(1/d), where
S/V is a surface to volume ratio, d is a spatial dimension and, 1=D/(2?), where ? is a permeability, and (iv) z=i(i??)1/2, where i is an imaginary unity, ? is a frequency and ?=D/(2?)2.

US Pat. No. 9,170,298

SYSTEM, METHOD AND COMPUTER-ACCESSIBLE MEDIUM FOR DESIGN FOR TESTABILITY SUPPORT FOR LAUNCH AND CAPTURE OF POWER REDUCTION IN LAUNCH-OFF-CAPTURE TESTING

New York University, New...

1. A non-transitory computer-accessible medium having stored thereon computer-executable instructions for modifying at least
one circuit, wherein, when a computer hardware arrangement executes the instructions, the computer arrangement is configured
to perform procedures comprising:
dividing the at least one circuit into a plurality of regions such that each scan cell of a plurality of scan cells belongs
to a single region, and the regions do not form a cycle;

levelizing the regions;
selecting a set of the scan cells of at least one first region that drive a plurality of interface registers that belong to
at least one second region as at least one interface register; and

inserting at least one shadow register into the at least one interface register.

US Pat. No. 9,075,122

METHOD, SYSTEM AND COMPUTER-ACCESSIBLE MEDIUM FOR PROVIDING MULTIPLE-QUANTUM-FILTERED IMAGING

New York University, New...

1. A non-transitory computer-accessible medium having stored thereon computer-executable instructions configured for generating
B0 corrected Nuclear Magnetic Resonance (NMR) data regarding at least one arbitrary anatomical sample, wherein, when a computer
arrangement executes the instructions, the computer arrangement is configured to perform procedures comprising:
causing the generation of at least one NMR signal utilizing phase differences of excitation pulses, wherein the at least one
NMR signal relates to at least one multiple-quantum coherence existing in the arbitrary anatomical sample while in a presence
of B0 inhomogeneities associated with the at least one arbitrary anatomical sample;

receiving the at least one generated NMR signal;
generating the B0 corrected NMR data from the received at least one NMR signal by applying a B0 correction to the received at least one NMR signal in order to remove destructive interference in the presence of B0 inhomogeneities, contributing to the received at least one NMR signal; and

at least one of displaying or storing in a storage arrangement the B0 generated corrected NMR data.

US Pat. No. 10,226,443

METHODS FOR TREATING PSORIATIC ARTHRITIS

New York University, New...

1. A method for treating a subject afflicted with psoriatic arthritis, wherein the subject afflicted with psoriatic arthritis exhibits symptoms characteristic of psoriasis of the skin selected from the group consisting of pain, swelling, or stiffness in one or more joints; joints that are red or warm to the touch; dactylitis; pain in and around the feet and ankles; and lower back pain, and the subject does not exhibit symptoms characteristic of inflammatory bowel disease selected from the group consisting of abdominal pain; vomiting; diarrhea; rectal bleeding; severe pelvic cramps; and weight loss, the method comprising administering to the subject a therapeutically effective amount of at least one medium-chain fatty acid or an ester/salt thereof or a composition thereof selected from hexanoic acid and heptanoic acid or an ester/salt thereof, wherein the at least one medium-chain fatty acid or an ester/salt thereof or composition thereof is administered orally or anally, wherein the subject afflicted with psoriatic arthritis has decreased bacterial diversity of gut microbiota, and wherein administering the therapeutically effective amount of the at least one medium-chain fatty acid or an ester/salt thereof or composition thereof treats the subject afflicted with psoriatic arthritis.
US Pat. No. 9,873,661

SMALL MOLECULE MALARIAL ALDOLASE-TRAP ENHANCERS AND GLIDEOSOME INHIBITORS

New York University, New...

1. A method comprising:
providing a complex of Aldolase of an apicomplexan organism and thrombospondin-related anonymous protein (TRAP) of an apicomplexan
organism;

providing one or more candidate compounds;
contacting the candidate compounds and the complex in vitro to determine which of the one or more candidate compounds stabilize
the complex; and

screening the compounds, determined to stabilize the complex, in vitro for their ability to kill and/or inhibit growth of
an apicomplexan organism.

US Pat. No. 9,644,023

COMPOSITIONS AND METHODS FOR PHAGOCYTE DELIVERY OF ANTI-STAPHYLOCOCCAL AGENTS

New York University, New...

1. A binding molecule comprising:
a first binding domain capable of binding to a glycosylated staphylococcal surface protein, said first binding domain comprising
a variable domain of an immunoglobulin heavy chain, wherein said immunoglobulin heavy chain comprises an amino acid sequence
of SEQ ID NO: 60, 62, 64 or 66; and

a second binding domain coupled to said first binding domain and comprising a fibronectin type III (FN3) domain that is capable
of binding to a staphylococcal leukotoxin.

US Pat. No. 9,603,792

SYSTEM AND METHOD FOR CORRECTION OF INTRACEREBRAL CHEMICAL IMBALANCES

New York University, New...

1. An osmotic pump, comprising:
a first agent reservoir;
a first solute chamber;
a first flexible membrane separating the first agent reservoir from the first solute chamber;
a first valve moveable between an open position in which the first agent reservoir is open to an outlet of the osmotic pump
and a closed position in which the first agent reservoir is sealed with respect to the osmotic pump outlet; and

a valve control mechanism selectively moving the first valve between its open and closed position in response to an instruction
received from a processor.

US Pat. No. 9,475,856

CHIMERIC FGF21 PROTEINS WITH ENHANCED BINDING AFFINITY FOR ?-KLOTHO FOR THE TREATMENT OF TYPE II DIABETES, OBESITY, AND RELATED METABOLIC DISORDERS

New York University, New...

1. An isolated chimeric protein comprising:
an N-terminus coupled to a C-terminus, wherein the N-terminus comprises an N-terminal portion of fibroblast growth factor
(FGF) 21, and the C-terminus comprises a C-terminal portion of FGF19, wherein the N-terminal portion of FGF21 comprises an
amino acid sequence beginning at residue 29 and ending at any one of residues 167-197 of SEQ ID NO:152, wherein the C-terminal
portion of FGF21 beginning at any one of residues 167-197 and ending at residue 209 of SEQ ID NO: 152 is progressively replaced
with a C-terminal portion of FGF19 beginning at any one of residues 169-204 and ending at residue 216 of SEQ ID NO:1.

US Pat. No. 9,422,237

COVALENTLY PATTERNED GRAPHENE SURFACES BY A FORCE ACCELERATED CYCLOADDITION REACTION

New York University, New...

1. A method of covalently patterning soft matter onto the basal plane of a graphene surface, said basal plane comprising a
first reactive element and said method comprising the steps of:
(a) coating an elastomeric tip array with an ink mixture comprising a second reactive element consisting of or bound to the
soft matter

(b) inducing a localized force-accelerated reaction between the first reactive element and the second reactive element by
mechanical application of the elastomeric tip array to the graphene surface, resulting in a covalent bond between the first
and second reactive elements; and

(c) rinsing the graphene surface to remove unbound ink.

US Pat. No. 9,369,328

SYSTEM AND METHOD FOR PROVIDING CHANNEL EQUALIZATION IN ORTHOGONAL FREQUENCY DIVISION MULTIPLEXING (OFDM) WIRELESS SYSTEMS

New York University, New...

1. A non-transitory, computer-readable medium providing computer-executable instructions for estimating a response of a communication
channel, wherein, when executed by a computer arrangement, the instructions specifically configure the computer arrangement
to execute procedures comprising:
receiving, via the communication channel, a signal comprising a plurality of symbols, each symbol comprising (i) one or more
pilot sub-carriers and (ii) one or more non-pilot sub-carriers;

for each of the one or more pilot sub-carriers, determining a pilot sub-carrier response and a pilot sub-carrier metric; and
for each of the one or more non-pilot sub-carriers:
determining a non-pilot sub-carrier metric; and
if the non-pilot sub-carrier metric satisfies a predetermined criterion, determining a particular component of a non-pilot
sub-carrier response as a function of components, different from the particular component, of one or more pilot sub-carrier
responses.

US Pat. No. 9,295,526

COCHLEAR IMPLANT WITH IMPROVED ELECTRODE ARRAY AND CONTROLLER

New York University, New...

1. A multi joint robot comprising:
a plurality of multi joint actuator units interconnected mechanically and controllable electronically;
each of the plurality of multi joint actuator units including at least two micro-tilt stages, an inner column disposed between
the central discs, and at least one wire in communication with the at least two micro-tilt stages, each of the at least one
wire having a terminal wire end protruding from each of the at least two micro-tilt stages, respectfully;

an outer surface of the multi joint robot configured to receive a cochlear implant, each terminal wire end electrically engageable
with a conductive strip of the cochlear implant;

each of the plurality of multi joint actuator units being capable of independent remote activation by electronic communication.

US Pat. No. 9,271,808

ORTHODONTIC METHODS AND DEVICES

New York University, New...

1. A method of moving a tooth to a desired position within a patient's mouth comprising:
a) perforating or pricking tissue in the oral cavity adjacent the tooth to be moved sufficient to induce an inflammatory response
in the tissue wherein the perforating or pricking is performed 1 to 5 mm from the alveolar crest to produce perforations,
wherein none of the perforations penetrate medullary bone, wherein all of the perforations extend through gingival tissue
into cortical bone, and wherein expression of one or more inflammatory markers is increased in the tissue by at least 50%
as compared to the expression of the one or more inflammatory markers prior to any perforations; and

b) installing an orthodontic appliance in the patient's mouth to exert force on the tooth in the direction of the desired
position.

US Pat. No. 9,261,497

METHOD OF TREATING CANCER WITH MODULATORS OF SCFSKP2

New York University, New...

1. A method of treating endometrial cancer in a subject, said method comprising: selecting a subject with endometrial cancer
and administering to the subject a compound from the group consisting of

US Pat. No. 9,248,128

METHOD FOR ENHANCING REMYELINATION USING GLI1 INHIBITORS

NEW YORK UNIVERSITY, New...

1. A method for enhancing remeyelination in a subject in need thereof comprising administering to said subject an effective
amount of a Gli1 inhibitor.
US Pat. No. 9,168,214

METHODS OF INCREASING COLLAGEN FORMATION AND CELLULAR MIGRATION IN INTACT SKIN

New York University, New...

1. A method of increasing collagen formation in intact skin comprising administering topically or locally to intact skin a
composition wherein the active ingredient consists of Vascular Endothelial Growth Factor (VEGF) in an effective amount to
increase collagen formation in the intact skin.

US Pat. No. 9,082,888

INVERTED ORTHOGONAL SPIN TRANSFER LAYER STACK

New York University, New...

1. A magnetic device comprising:
a pinned magnetic layer having a first fixed magnetization vector with a first fixed magnetization direction;
a free magnetic layer having a variable magnetization vector having at least a first stable state and a second stable state;
a first non-magnetic layer spatially separating the pinned magnetic layer and the free magnetic layer;
a reference magnetic layer having a second fixed magnetization vector with a second fixed magnetization direction; and
a second non-magnetic layer spatially separating the free magnetic layer and the reference magnetic layer, wherein a magnetic
tunnel junction is formed by the free magnetic layer, the second non-magnetic layer, and the reference magnetic layer, wherein
application of a current pulse, having a selected amplitude and duration, through the magnetic device switches the variable
magnetization vector, and wherein the magnetic tunnel junction is spatially located below the pinned magnetic layer.

US Pat. No. 10,002,444

SYSTEM, METHOD AND COMPUTER-ACCESSIBLE MEDIUM FOR JOINT MAGNETIC RESONANCE-POSITRON EMISSION TOMOGRAPHY RECONSTRUCTION USING MULTI-SENSOR COMPRESSED SENSING

New York University, New...

1. A non-transitory computer-accessible medium having stored thereon computer-executable instructions for generating at least one first image and at least one second image of at least one tissue which are different from one another, wherein, when a computer arrangement executes the instructions, the computer arrangement is configured to perform procedures comprising:receiving combined information related to a combination of first positron emission tomography (PET) imaging information and first magnetic resonance (MR) imaging information data as a single data set;
separating the combined information into at least two dimensions into a separated information, at least one first of the at least two dimensions corresponding to the first PET imaging information and at least one second of the at least two dimensions corresponding to the first MR imaging information;
generating second PET imaging information and second MR information by performing a joint thresholding procedure on the first PET imaging information and on the first MR imaging information;
automatically modelling a resolution of the second PET imaging information using the second MR imaging information; and
generating the at least one first image and the at least one second image based on the second PET imaging information, (ii) the second MR information, and (iii) the modelled resolution of the second PET imaging information.
US Pat. No. 9,554,997

POLYMER CARRIER

New York University, New...

1. A carrier polymer for delivering bioactive agent, wherein the carrier polymer comprises the amino acid sequence selected
from the group consisting of SEQ ID NOS: 3-17 and forms a hydrophobic pore with a threshold radius of 73 Å and a diameter
that is 2-6 nm.

US Pat. No. 9,533,115

SYSTEM AND METHOD FOR DIAGNOSIS AND TREATMENT OF A BREATHING PATTERN OF A PATIENT

NEW YORK UNIVERSITY, New...

1. A positive airway pressure system which delivers of a flow of breathable gas at a positive treatment pressure with respect
to ambient air pressure to an entrance of a patient's airways in order to assist in treating a sleeping disorder, the positive
airway pressure system comprising:
a flow generator which generates a flow of breathable gases to be supplied to a patient;
a flow sensor measuring data indicative of the patient's breathing patterns; and
at least one hardware processor which receives the measured data corresponding to the flow of breathable gases from the flow
sensor and analyzes the data, the hardware processor determines whether to alter the pressure supplied by the flow generator
to the airway of the patient based, at least in part, on the indication of the patient's breathing patterns, wherein the hardware
processor automatically increases a pressure supplied to the patient when the hardware processor determines that an indication
of the patient's breathing patterns representative of a change from an awake state to an asleep state has occurred, the indication
of the patient's breathing patterns representative of a change from an awake state to an asleep state including at least one
of a regularity of breathing or a regular period of obstructions.

US Pat. No. 9,453,060

PROTEIN ENGINEERED SYSTEMS FOR DELIVERY OF MOLECULES

New York University, New...

1. A peptide comprising the sequence of SEQ ID NO:1.

US Pat. No. 9,421,218

COMPOSITIONS AND METHODS FOR TREATMENT OF MELANOMA

New York University, New...

1. A method for treating melanoma comprising administering to a subject in need thereof an amount effective to treat melanoma
of a composition comprising an agent which inhibits the expression of a nucleic acid sequence selected from the group consisting
of: SEQ ID NOS: 9, 11 and 9+11 and a pharmaceutically acceptable carrier, wherein administration of the composition inhibits
the growth and viability of melanoma cells in said subject.

US Pat. No. 9,373,160

SYSTEM, METHOD AND COMPUTER-ACCESSIBLE MEDIUM FOR RESTORING AN IMAGE TAKEN THROUGH A WINDOW

New York University, New...

23. A non-transitory computer-accessible medium having stored thereon computer-executable instructions for modifying at least
one image, wherein, when a computer hardware arrangement executes the instructions, the computer arrangement is configured
to perform procedures comprising:
receiving first image information for the at least one image;
generating second image information by separating the first image information into at least two overlapping images;
generating at least one weight for use by a prediction procedure by (i) minimizing a mean squared error over a dataset of
corresponding noisy and clean image pairs, and (ii) reducing a loss of the mean squared error using a Stochastic Gradient
Descent; and

modifying the at least one image using the prediction procedure based on the second image information.

US Pat. No. 9,082,950

INCREASED MAGNETORESISTANCE IN AN INVERTED ORTHOGONAL SPIN TRANSFER LAYER STACK

New York University, New...

1. A magnetic device comprising:
a pinned magnetic layer having a first fixed magnetization vector with a first fixed magnetization direction;
a free magnetic layer comprising a first body-centered cubic material and having a variable magnetization vector having at
least a first stable state and a second stable state;

a first non-magnetic layer spatially separating the pinned magnetic layer and the free magnetic layer and including a second
body-centered cubic material that interfaces with the first body-centered cubic material;

a reference magnetic layer having a second fixed magnetization vector with a second fixed magnetization direction; and
a second non-magnetic layer spatially separating the free magnetic layer and the reference magnetic layer, wherein a magnetic
tunnel junction is formed by the free magnetic layer, the second non-magnetic layer, and the reference magnetic layer, wherein
application of a current pulse, having a selected amplitude and duration, through the magnetic device switches the variable
magnetization vector, and wherein the magnetic tunnel junction is spatially located below the pinned magnetic layer.